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I. Introduction 
 
The physical health of psychiatric patients has been an issue long neglected. Nevertheless, 
psychiatric patients, especially the most severe ones, suffer from numerous and various physical 
health conditions, often little recognised and treated. In the last years, the scientific community 
acknowledged the problem and began investigating the field. To this end, Leucht and colleagues 
(2007) examined thoroughly the issue in their publication “Physical illness and schizophrenia”, a 
review of existing knowledge on physical comorbidity in schizophrenic patients up to 2007. The 
authors identified many different illnesses that arise in schizophrenic patients. On the whole, they 
have a greater physical morbidity and mortality compared to the general population. Approximately 
60% of the excess mortality results from natural causes (Bradshaw, Lovell and Harris, 2005). The 
results of Leucht’s review will be reported more in detail in the chapter “Literature review”. 
Such situation is complicated by many aspects, that range from self-neglect due to 
psychopathology to stigma by health professionals and disparities in health care access. Literature 
has identified several risk factors involved in the development of physical illness in psychiatric 
patients. Among these there are both non-modifiable and modifiable factors. The former include 
gender, age, family history, socio-economical status and antipsychotics side effects, while the latter 
include hypertension, dyslipidemia, glucose intolerance or insulin resistance, abdominal obesity 
(which altogether define the “metabolic syndrome” [MS]), diabetes, obesity, smoking, psychiatric 
symptoms and unhealthy lifestyles. Psychiatric patients are at an increased risk of cardiovascular 
diseases (CVD) and other diseases because of a higher prevalence of and inadequate attention to 
such modifiable risk factors (Allison et al., 2009). 
A variety of interventions is available to prevent these risk factors and to treat the related 
conditions, from pharmacological interventions to non-pharmacological ones. However, in primary 
care settings as well as clinical ones, it is not always easy to implement interventions for health 
promotion or illness prevention for psychiatric patients. As Newall et al. (2012) note in their review, 
metformin is the most suitable agent for the prevention and treatment of weight gain associated with 
antipsychotic medication. Nevertheless, it should only be taken into account when lifestyle 
interventions fail, because at present no pharmacological treatment has sufficient evidence to 
recommend broad clinical usage (Maayan, Vakhrusheva and Correll, 2010b). On the other hand, the 
combination of pharmacological and non-pharmacological strategies should be studied in more 
detail (Maayan and Correll, 2010a). As stated by several systematic reviews and meta-analyses on 
physical health promotion (in particular, weight management) in psychiatry, it is indeed possible to 
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implement successful health promotion strategies in psychiatric settings (Caemmerer, Correll and 
Maayan, 2012; Bonfioli, Berti, Goss, Muraro and Burti, 2012; Álvarez-Jiménez, Hetrick, González-
Blanch, Gleeson and McGorry, 2008; Faulkner, Cohn and Remington, 2007). A number of other 
reviews have explored the issue on a more general level, as further explained under the paragraph 
"Intervention strategies".  
In accordance with all the evidence produced by literature until now and all the needs 
identified, we have proposed a health promotion intervention designed specifically to support 
healthy lifestyles in patients with severe mental disorders (SMD) and we have studied its efficacy. 
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II. Literature review 
 
2.1 Mortality 
The high risk of premature death experienced by the mentally disordered has been known 
from English vital statistics for 150 years. The causes of this excessive mortality arise, broadly 
speaking, from the mental disorder itself and from the altered way in which the affected are 
compelled, or elect, to live (Harris & Barraclough, 1998). Overall mortality in people with 
schizophrenia is reported to be twice as high as that in the general population. Suicide and accidents 
account for about 40% of this excess mortality, however the rest is due to physical illness (Brown, 
1997; National Association of State Mental Health Program Directors [NASMHPD], 2006). Suicide 
is the most frequent cause of unnatural death, whereas CVD and respiratory disease account for the 
majority of natural deaths in schizophrenia (Conley et al., 2005). According to the meta-analysis on 
excess mortality in mental disorders by Harris and Barraclough (1998), combined studies on 
mortality in schizophrenia gave a death risk of 1.6 times that expected. Deaths from natural causes 
were 1.4 times more than expected, accounting for 62% of the excess deaths. The greatest number 
of excess deaths were from infectious, respiratory and digestive system disorders. In bipolar 
disorder they found death risk to be twice that expected, with deaths from natural causes 1.5 times 
more than expected, accounting for 46% of the excess deaths (Harris and Barraclough, 1998). 
According to a study conducted in American public mental health agencies, psychiatric 
patients (especially those with schizophrenia, other psychoses, major depressive disorder, bipolar 
disorder and attention deficit/hyperactivity disorder, defined as major mental illness) lose from 13 
to 32 years of potential life and die at younger ages (Colton and Manderscheid, 2006). Also, 
according to the same study, the relative risk of death of psychiatric patients is higher than for the 
general population. The 2006 technical report by the United States of America (USA) NASMHPD 
points out that the rate of serious morbidity and mortality in people with SMD is not only higher 
than the general population one, but has also accelerated so much that they are now dying 25 years 
earlier than the general population (NASMHPD, 2006). 
Conley et al. (2005) in a post-mortem study examined the association between coronary 
atherosclerosis and schizophrenia. MS is a co-occurrence of atherosclerosis risk factors and, as 
reported hereinafter, is common in schizophrenia patients. Coronary atherosclerosis in people with 
schizophrenia occurred independent of abnormal subcutaneous fat thickness and was inversely 
associated with weight, unlike the pattern of association with weight seen in the normal controls 
(Conley et al., 2005). However, the percentage of deaths due to CDV was similar in the 2 groups. 
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This, according to the authors, suggests that CVD in people with schizophrenia could relate less to 
weight than in the controls and more to other conditions, such as intrinsic metabolic differences, 
lifestyle differences or effects of antipsychotic medications (Conley et al., 2005). Anyway, 
mortality is directly related to the magnitude of weight gain (Tschoner et al., 2007) and, if that is the 
case, psychiatric patients need to pay even more attention to adopting healthier lifestyles. 
 
2.2 Physical comorbidity 
The book published by Leucht and colleagues in 2007 provides a comprehensive review of 
research evidence on the prevalence of physical diseases in people with schizophrenia up to that 
date (Table 1). The amount of research that has been done on the issue is remarkable, yet health 
systems and institutions have not taken consistent measures to deal with physical comorbidity in 
mental health (Leucht et al., 2007). According to this extensive work, it is undeniable that there are 
a number of physical diseases that are more frequent in people with schizophrenia. Diseases in bold 
in the table are the most common, according to the authors. 
Some of the key areas in which comorbidity in psychiatric patients occurs will be examined 
hereinafter. 
 
Table 1 Summary of physical diseases that occur with increased or decreased frequency in schizophrenia (from 
Leucht et al., 2007) 
MeSH disease category Physical disease with increased frequency in schizophrenia 





Respiratory tract diseases 
Nervous system diseases 
 
Urological and male genital diseases 
Female genital diseases and 
pregnancy complications 
Cardiovascular diseases 
Skin and connective tissue diseases 
Nutritional and metabolic diseases 
 
Endocrine system diseases 
Tuberculosis (+) 
HIV (++), hepatitis B ⁄ C (+) 
Cancer in general (-)* 
Osteoporosis ⁄ decreased bone mineral density (+) 
Poor dental status (+) 
Impaired lung function (+) 
Extrapyramidal side-effects of antipsychotic drugs (+), motor signs in 
antipsychotic naive patients (+), altered (reduced) pain sensitivity (+) 
Sexual dysfunction (+), prostate cancer (-) 
Obstetric complications (++), sexual dysfunction (+), hyperprolactinemia 
related side-effects of antipsychotics (irregular menses, galactorrhea etc.) (+) 
Cardiovascular problems (++) 
Hyperpigmentation (+)**, rheumatoid arthritis (-) 
Obesity (++), diabetes (+), metabolic syndrome including hyperlipidemia 
(+), polydipsia (+) 
Thyroid dysfunction (+), hyperprolactinemia (side-effect of a number of 
antipsychotics) (+) 
(++) very good evidence for increased risk (e.g. population-based studies), (+) good evidence for increased risk, (-) 
evidence for decreased risk. 
The table does not list physical diseases that have only been shown to be related to the aetiology of schizophrenia (e.g. 
influenza virus). There were no clearly increased rates of physical diseases in the categories parasitic diseases, digestive 
system diseases, otorhinolaryngological diseases, eye diseases, hemic and lymphatic diseases, congenital, hereditary, 
and neonatal diseases and abnormalities, immune system diseases, disorders of environmental origin, animal diseases, 
pathological conditions, signs and symptoms or these diseases were listed in another category. 
*The results on specific forms of cancer were mostly inconclusive due to contradictory results and limited power. 
**A side-effect of chlorpromazine, probably not a problem of most other antipsychotics. 
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Obesity 
In 2005, the National Institute of Mental Health (NIMH, USA) has initiated the programme 
“Health Behavior Change in People with Mental disorders”. Allison et al. (2009) report about the 
meeting held by research experts in the frame of this programme to address obesity, nutrition and 
physical activity among psychiatric patients. In studies that compared a sample of people with SMD 
with a sample from the third National Health and Nutrition Examination Survey (NHANES III) in 
USA, a significantly greater percentage of people with SMD were found to be obese than the 
general population (Allison et al., 2009). Daumit et al. (2003) in a community-based sample found 
that individuals with SMD had a higher prevalence of obesity than the general population of USA 
and Maryland, when adjusted for age, ethnicity and smoking status. In particular, the prevalence of 
obesity was two times greater in women with SMD compared to the general population (60% v. 
28.5%) and also to men with SMD (60% v. 29%; Daumit et al., 2003). According to the authors, the 
high prevalence of obesity is likely due in large part to lifestyle factors. The problem is especially 
severe in women with psychiatric conditions, although the use of atypical (or second generation) 
antipsychotics accounts for 75% of obesity in men. Coodin (2001) obtained a similar result in a 
Canadian sample of schizophrenic patients (schizophrenia sample: mean Body Mass Index (BMI) in 
men 28.5, mean BMI in women 30; general population sample: mean BMI in men 26.3, mean BMI 
in women 24.3). Men and women with schizophrenia had respectively a mean BMI just below and 
above the threshold for obesity (BMI > 30). Data refers to the American population, however, 
similar results have been found in the Italian population. According to the study by Carpiniello and 
colleagues (2008), the mean BMI of a sample of 126 schizophrenic patients was 26.8. The 
prevalence of obesity was 26.2%, 2.8 times higher than the Italian general population (9.8%). Forty-
six percent (46.8%) of the sample had visceral obesity, a proportion 1.7 times higher than the Italian 
national mean (31%). In particular, visceral obesity was higher in females (F = 60.5%; M = 37.3%, 
p<0.05). Tridente et al. (2005) found 21% of their sample (formed by patients treated with 
antipsychotics) to be obese at the beginning of pharmacotherapy, against the 10% of the general 
population of Campania. At the end of the study the percentage of overweight subjects went from 
32% to 46% and the percentage of obese subjects from 21% to 33%. Similar results have been 
replicated in Germany by Theisen and colleagues (2001), who found obesity in 56% of a sample of 
young patients with schizophrenia spectrum disorders, compared to 33% in German general 
population. Interestingly, the distribution of BMI values in the psychiatric population tends to be 
different from the distribution in the general population: indeed, as pointed out by Allison et al. 
(2009), people with schizophrenia tend to be over-represented in the obese range of BMI values. 
 - 12 - 
Another aspect to take into account is one underlined by Sharpe, Byrne, Stedman and Hills 
(2005), who measured resting energy expenditure in a small sample of males with schizophrenia 
treated with clozapine and found it to be lower than predicted. Resting energy expenditure is the 
amount of energy required by the body for a 24-hour period during resting conditions. 
There is evidence that obesity has contributed to a widening of the mortality gap of 
psychiatric patients compared to the general population (Megna, Schwartz, Siddiqui & Herrera 
Rojas, 2011) and it is, indeed, a major cause of the development of other risk factors, such as 
diabetes and MS, which altogether contribute to double the risk of CVD. 
Abdominal obesity 
Abdominal (or visceral) obesity is defined as a form of obesity due to excessive deposition 
of fat in the abdominal viscera and omentum, rather than subcutaneously. Cut-offs for abdominal 
obesity are shown in Table 2. Abdominal fat distribution can be measured by indirect (waist-to-hip 
ratio, BMI) and by direct means (computerized axial tomography, magnetic resonance imaging) 
(Thakore, Mann, Vlahos, Martin and Reznek, 2002). 
Abdominal obesity is associated with MS. In a systematic review and meta-analysis of 126 
studies (Mitchell et al., 2013), waist size was most useful in predicting high rate of MS in 
individuals with schizophrenia. The proportion of overweight according to the National Cholesterol 
Education Program’s Adult Treatment Panel (ATP) definition of abdominal obesity was 49.4% 
(Mitchell et al., 2013). 
There are evidences of body composition differences between patients with schizophrenia 
and healthy controls, with the former having significantly higher waist-to-hip ratios and over 3 
times as much visceral fat (Holt, Pevelert and Byrne, 2004; Thakore et al., 2002). No difference in 
intra-abdominal fat distribution was found by Thakore et al. (2002) between drug-naïve and drug-
free schizophrenic patients, which once again suggests baseline differences between these patients 
and the general population. Sugawara and colleagues (2012) analysed the body composition in a 
sample of schizophrenic patients using bioelectrical impedance analysis and compared them to 
healthy subjects. They found higher body fat, lower fat-free mass, lower muscle mass and lower 
body water in male schizophrenic patients compared to healthy controls. The correlation was 
opposite in females, which could be explained by the effect of oestrogen on body composition. 
 
Metabolic syndrome 
MS is defined in different ways as a cluster of risk factors for CVD (see Table 2). According 
to the criteria proposed by the National Cholesterol Education Program’s ATP III, MS can be 
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diagnosed when 3 of 5 of the following risk factors are present: abdominal obesity, high 
triglycerides, low high density lipoprotein (HDL) cholesterol, high blood pressure and high fasting 
glucose (Grundy, Brewer, Cleeman, Smith and Lenfant, 2004).  
In data derived from the Clinical Antipsychotic Trials of Intervention Effectiveness 
(CATIE) study, MS was present in 41% of schizophrenia patients, compared to 25.1% in healthy 
women and 36% in healthy men (Allison et al., 2009). Patients also had a higher prevalence of 
almost all individual criteria for MS. According to the meta-analysis by Mitchell et al. (2013), the 
overall rate of MS in individuals with schizophrenia was 32.5%. In the analysis of specific 
metabolic abnormalities, the authors found: 49.4% rate of abdominal obesity; 38.7% rate of high 
blood pressure; low HDL in 42.6% of cases; 39.3% rate of hypertriglyceridemia; 19.5% rate of 
hyperglycaemia. High density lipoprotein (HDL) cholesterol levels were found to be decreased and 
triglycerides increased in chronic schizophrenic patients, as reported by Holt and colleagues (2004). 
Hypertriglyceridemia can be linked to some second-generation antipsychotics (Tschoner et al., 
2007). 
As a whole, the aforementioned abnormalities are associated with an increased risk of type 2 
diabetes and cardiovascular disease (De Hert, Detraux, van Winkel, Yu and Correll, 2012; von 
Hausswolff-Juhlin, Bjartveit, Lindström and Jones, 2009). As a consequence, the higher prevalence 
of MS in people with schizophrenia may provide an explanation for the increased prevalence of 
diabetes and CVD (Holt et al., 2004). As noted in the Conference of the American Heart 
Association and the National Heart, Lung, and Blood Institute held in 2004, most people with MS 
have insulin resistance, conferring increased risk for type 2 diabetes too (Grundy et al., 2004). 
Moreover, diabetes in itself is a risk factor for CVD. Individuals with MS seemingly are also 
susceptible to other conditions (polycystic ovary syndrome, fatty liver, cholesterol gallstones, 
asthma, sleep disturbances and some forms of cancer) (Grundy et al., 2004). ATP III recommends 
that obesity be the primary target of intervention for MS and, therefore, first-line therapy should be 
weight reduction reinforced with increased physical activity (Grundy et al., 2004). 
It is also known that people taking antipsychotic medications have reduced metabolic 
expenditure, as mentioned by Amiel, Mangurlan, Ganguli and Newcomer (2008) in their review, 
which implies a greater difficulty in managing their weight. 
In an Italian sample of 76 patients treated with second generation antipsychotics, Tarricone 
et al. (2006) found that all of them had higher mean glycaemia and triglyceridaemia comparing to a 
reference group of patients without psychiatric history. According to the results of this study, 
psychiatric patients had a higher risk of hyperglycaemia and hypertriglyceridaemia even without 
fulfilling other risk factors for MS (Tarricone et al., 2006). 
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Table 2 Definition of MS according to different guidelines (adapted from Mitchell et al., 2013) 
 American Heart 
Association, 
National Heart, 
Lung and Blood 
Institute (Adult 
Treatment Panel 















Women: > 88 cm 
(35 inches)                                  
Men: > 102 cm 
(40 inches) 
Women: > 80 cm 
(31.5 inches)                                






Women > 88 cm 
Men > 102 cm 
Women: > 0.85 
Men: > 0.9 
Blood pressure ≥130/≥85 mmHg ≥130/≥85 mmHg ≥130/≥85 mmHg  
HDL cholesterol Men < 40 mg/dl 
(1.04 mmol/l) 
Women < 50 
mg/dl (1.29 
mmol/l) 
Men < 40 mg/dl 
(1.04 mmol/l) 
Women < 50 
mg/dl (1.29 
mmol/l) 
Men < 40 mg/dl 
(1.04 mmol/l) 




Triglycerides ≥150 mg/dl (1.7 
mmol/l) 
≥150 mg/dl (1.7 
mmol/l) 
≥150 mg/dl (1.7 
mmol/l) 
 
Fasting glucose ≥100 mg/dl (5.6 
mmol/l) 
≥100 mg/dl (5.6 
mmol/l) 





Diabetes has been linked with schizophrenia for a long time. The prevalence of diabetes and 
impaired glucose tolerance has been reported to be 1.5- to 3-fold higher in people with 
schizophrenia than the general population (Smith et al., 2008; Holt et al., 2004; American Diabetes 
Association [ADA], 2004). 
According to Holt et al. (2004) up to 30% of people with schizophrenia have a family 
history of type 2 diabetes and genetic factors appear to be important in the aetiology of 
schizophrenia and diabetes. There are, in fact, some reports suggesting even that schizophrenia 
itself may be associated with diabetes independently of antipsychotic drugs, however Leucht et al. 
(2007) do not consider these results to be representative. It is plausible that lifestyle factors, poor 
access to good nutrition, inactivity and weight gain induced by antipsychotics side-effects link 
diabetes with schizophrenia. 
Given the high overall prevalence of diabetes and its frequent asymptomatic presentation, it 
would be logical to monitor all patients with schizophrenia for its presence (Holt et al., 2004). 
 
 - 15 - 
Cardiovascular diseases 
The Framingham Heart Study and other studies have identified key modifiable risk factors 
for CVD, including obesity, smoking, hyperglycaemia, hypertension and dyslipidemia (Allison et 
al., 2009). Other risk factors are age, male sex, diabetes, serious pulmonary disease and prior CVD 
(Leucht et al., 2007).  
Overall, the studies reviewed by Leucht et al. (2007) confirm that people with schizophrenia 
have higher rates of CVD. CVD (including acute coronary syndrome, chronic ischemic heart 
disease, arrhythmia, heart failure and stroke) was also significantly higher (27% vs. 17%) in people 
with schizophrenia than controls in a recent population-based study by Bresee, Majumdar, Patten 
and Johnson (2010). This was particularly true for younger age, moreover female sex offered no 
cardiovascular protection, differently from the general population. CVD risk factors (defined as 
diabetes, hypertension and dyslipidemia) were also examined in this study. Diabetes was found to 
be almost twice as common in people with schizophrenia (10% vs. 6%). The other risk factors were 
similarly distributed, however patients with schizophrenia were more likely to have multiple risk 
factors (Bresee et al., 2010). Bernardo and colleagues (2009) found prevalent and under-diagnosed 
CVD risk factors (especially smoking, hypercholesterolemia, lack of exercise, hypertriglyceridemia 
and obesity) in schizophrenia, with insufficient therapeutic management. Important conditions such 
as dyslipidemia remain undetected and even a sedentary lifestyle might not be recognised as a CVD 
risk factor (Bernardo et al., 2009). The study by Bernardo and colleagues (2009) suggests that even 
in low cardiovascular risk areas (i.e. a southern European country) CVD risk factors are present 
among patients with schizophrenia. A study by Conley and colleagues (2005) identified a higher 
percentage of death by CVD in people with schizophrenia, unrelated to weight. The authors suggest 
that CVD mortality in this population may be associated more with intrinsic metabolic differences, 
lifestyle differences or effects of antipsychotic medication, rather than with weight alone. 
Kang et al. (2000) documented ECG abnormalities in patients treated with clozapine. Most 
of the abnormalities were essentially benign, therefore not hindering treatment with clozapine. 
Nevertheless, the authors conclude that treatment should be accompanied by judicious monitoring 
(Kang et al., 2000). A documented side effect that has been associated with several antipsychotic 
drugs and with polypharmacy is QT prolongation (von Hausswolff-Juhlin et al., 2009). There are 
several conditions for which prolonged QT interval has been associated with an increased risk of 
torsades de pointes and sudden death (Hennekens, 2007). Leonard et al. (2013) reviewed studies on 
the risk of sudden cardiac death in antipsychotics users and found that haloperidol and 
chlorpromazine were associated with ~2-fold greater risks of sudden death/ventricular arrhythmias 
and 3- and 4-fold greater risks of death (respectively), compared to olanzapine.  
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Osteoporosis 
Osteoporosis is defined as a bone mineral density of more than 2.5 standard deviations 
below the mean value for peak bone mass in young adults, when measured with dual-energy X-ray 
absorptiometry (Leucht et al., 2007). Osteoporosis can cause serious bone fractures. The studies 
identified by Leucht and colleagues (2007) in their review consistently show that loss of bone 
mineral density is prevalent in schizophrenia. Takkouche, Montes-Martínez, Gill and Etminan 
(2007) in their meta-analysis found an increase in the risk of fractures in antipsychotics users of 
60%. Hummer et al. (2005), reported the presence of low bone mineral density even in young 
patients with schizophrenia, especially in males. They hypothesised that negative symptoms could 
be related to vitamin D deficiency, because patients tend to be sedentary and go out less and 
therefore expose to sun less. Positive symptoms, on the other hand, can lead to disordered food 
intake and therefore to nutritional deficits (Hummer et al., 2005). 
Vitamin D supplement can help to prevent fractures through improved skeletal health and 
calcium absorption (Geddes & Inderjeeth, 2013). In case of vitamin D deficiency or decrease of 
bone mineral density, supplementation is recommended (Hummer et al., 2005). According to the 
same authors, preventive measures for osteoporosis in patients with schizophrenia should be taken, 
including information about a balanced diet, motivation to regular physical exercise, avoidance of 
tobacco, caffeine and alcohol, and sufficient exposure to sunlight. 
 
2.3 Mechanisms 
The understanding of mechanisms involved in the development of physical comorbidities in 
psychiatric patients is obviously important, given the implications for prevention and treatment. 
Although a certain level of morbidity and mortality appears to be inherent to the disease itself, other 
factors such as behaviour, lifestyle, and pharmacological treatment, are secondary to common 
symptoms of schizophrenia (e.g. apathy leading to obesity and decreased propensity to exercise), or 
caused/augmented by drug treatment (e.g. weight change, sedation) and may also play a role (von 
Hausswolff-Juhlin et al., 2009). As a result, both non-pharmacologic and pharmacologic factors can 
contribute to the issue and they can interact with each other.  
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Pharmacological factors 
Antipsychotics side effects 
Weight gain and abnormalities in lipid and glucose metabolism induced by antipsychotic 
treatment can increase risk for CVD and diabetes in this population (Amiel et al., 2008). Atypical 
antipsychotics have been associated with a higher prevalence of obesity (Megna et al., 2011). 
Different antipsychotics have demonstrated different weight-gain liabilities. In the short term, 
clozapine has the highest risk of weight gain while ziprasidone has the lowest risk. Other atypical 
antipsychotics set on different positions of this spectrum. When data from multiple clinical trials 
lasting 52 weeks or longer were pooled by Allison et al. (2009), the mean weight gain was >10 kg 
over one year in patients who received olanzapine within the commonly used dose range. In the 
long term, the differences displayed by these antipsychotics are diminished (Megna et al., 2011). 
The effect of antipsychotics on weight can be both direct and mediated by non-pharmacological 
factors. The direct effects may be explained by genetic makeup as a possible modulating factor 
(Megna et al., 2011). As reported by the same authors, current pharmacogenomic approaches have 
estimated the number of candidate genes for antipsychotic-induced weight gain to be around 300. 
Such genes code for substances related to regulation of food intake.  
Treatment with second generation antipsychotic medications is also associated with an 
increased risk of dyslipidemia, insulin resistance, hyperglycaemia, and type 2 diabetes mellitus 
(Allison et al., 2009). The meta-analysis by Smith et al. (2008) found a relative risk of developing 
diabetes in patients treated with a second-generation antipsychotic of 1.32 (95% CI, 1.15-1.51) 
compared with first-generation antipsychotics. According to the authors, however, scientific 
evidence on the issue is not sufficient to be used as a guideline for switching antipsychotic 
medications or implementing diabetes screening and management protocols for schizophrenia. The 
mechanism by which antipsychotic drugs increase the risk of diabetes may be mediated primarily 
through weight gain rather than a direct effect on insulin resistance or β-cell function (Holt et al., 
2004). Tschoner et al. (2007), in their review, report on some studies that describe an increase of 
haemoglobin A1C (glycated haemoglobin) during treatment with olanzapine. Possible mechanisms 
include weight gain, changes of insulin secretion, development of peripheral insulin resistance and 
changes of cellular glucose uptake (Tschoner et al., 2007). Glycated haemoglobin is a form of 
haemoglobin that is measured primarily to identify the average plasma glucose concentration over 
prolonged periods of time. Higher amounts of glycated haemoglobin indicate poorer control of 
blood glucose levels over the months prior to the measurement. 
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Prolactin-increasing antipsychotics (such as typical antipsychotics, amisulpride and 
risperidone) are regularly mentioned as a risk factor for the development of osteoporosis, because 
they can lead to hypogonadism in both men and women (Leucht et al., 2007). 
Some antipsychotics can have cardiovascular side-effects. A potentially dangerous one is 
QTc lengthening, which, as previously mentioned, could cause torsade de pointes and sudden death 
(Leucht et al., 2007). 
Pharmacological treatments interact also with the non-pharmacological factors discussed in 
the section "Biological factors" and with other drugs, creating untoward drug-drug interactions 
(Leucht et al., 2007).  
 
Non-pharmacological factors 
A set of non-pharmacologic factors contribute to physical comorbidity in psychotic patients. 
Among the main factors are psychiatric symptoms (negative symptoms, cognitive disturbances, 
social isolation; Leucht et al., 2007), which can lead to self-neglect and poor compliance, unhealthy 
lifestyles (such as smoking, sedentariness, unhealthy diet, limited access to foods lower in calories 
and higher in nutrients) and medical abnormalities present even before pharmacologic treatment 
(Megna et al., 2011; Allison et al., 2009). We will explore hereinafter some of the main risk factors 
among those listed. 
Unhealthy lifestyles 
Literature about lifestyles in SMD patients encompasses exercise, diet, smoking and alcohol 
or substance abuse. 
According to the review by von Hausswolff-Juhlin et al. (2009), it has been shown that 
patients with schizophrenia exercise less than normal or than many other patient groups. Many 
factors are thought to underlie the lack of exercise in psychiatric patients, such as psychiatric 
symptoms, medications side effects and reduced social interaction leading to less opportunity for 
exercise. Lack of exercise can predispose patients with schizophrenia to develop MS and its 
associated risks. 
It has also been observed that schizophrenic patients have a poor diet, with high intake of fat 
and low intake of fibres, fruit and vegetables. The reasons for this are not known, although it has 
been hypothesized to be linked to factors such as unemployment, smoking and psychiatric 
symptoms (von Hausswolff-Juhlin et al., 2009). Psychiatric diseases themselves can contribute to 
increased storage of fat by changes in energy intake and expenditure, e.g. changes in patterns of 
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food intake and/or lifestyle (Tschoner et al., 2007). A poor access to good nutrition and inactivity 
may also contribute to the increased prevalence of type 2 diabetes (Holt et al., 2004). 
According to the review by von Hausswolff-Juhlin et al. (2009), as many as 75–92% of 
people with schizophrenia are smokers. Once they become smokers, they tend to smoke more 
heavily than the general population, extracting more nicotine from the cigarettes, generating more 
nicotine in the bloodstream and precipitating a greater addiction (von Hausswolff-Juhlin et al., 
2009). The high incidence of smoking implies a greater risk of experiencing the associated 
detrimental effects such as cardiovascular disease and respiratory morbidity and mortality. Also, 
smokers with schizophrenia are more likely than the general population of smokers to suffer 
medical consequences from smoking and to die of smoking-related diseases (Steinberg and 
Williams, 2007). 
Drug and alcohol abuse are a considerable problem in patients with severe mental health 
illnesses, such as schizophrenia. Nearly 35% of people with schizophrenia will abuse alcohol at 
some point during their lives (Llorca, 2008). 
Literature has also drawn attention to the fact that psychiatric patients seem to be little 
interested in their physical health and tend to self-neglect. Tridente et al. (2005) investigated in an 
Italian sample the interest of patients in their weight gain and found that 73,6% of the patients were 
not worried by their weight gain, with no correlation between BMI and level of worry. According to 
the authors, a passive attitude prevails especially among obese and overweight patients in the 
monitoring and control of their weight and physical health. 
Quality of medical care 
Although physical illness occurs in nearly 50% of patients, much of this morbidity is 
misdiagnosed or undiagnosed (Holt et al., 2004). There is evidence that schizophrenia patients have 
less access to healthcare (Leucht et al., 2007). This can relate to unemployment and lack of health 
insurance in countries that do not have a public health system. Nevertheless, psychiatric patients are 
less likely to receive health care in general. In some cases this occurs because in many current 
health systems psychiatry is not integrated into a general medical setting and, especially in 
developing countries, there is a lack of resources for performing the appropriate examinations 
(Leucht et al., 2007). Another issue is the stigma that can come from mental health professionals 
and other medical specialties too. Mental health professionals can consider physical complaints as 
an expression of the patient's mental illness and other professionals are often reluctant to treat 
people with schizophrenia. Often psychiatric institutions can be under-equipped to provide 
necessary clinical examinations and treatments for their patients (Leucht et al., 2007). Poor quality 
of health care may partly explain the excess mortality observed (Scott et al., 2012). 
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Scott, Platania-Phung and Happell (2012) reviewed the evidence on quality of care for 
people with comorbid SMD (including anxiety disorders, bipolar disorders, major depression, 
schizophrenia or other non-affective psychoses) and CVD or diabetes and the evidence on quality of 
screening for people receiving antipsychotics who are at risk for the development of CVD and 
diabetes. In the USA, testing levels for lipid and glucose in people prescribed antipsychotics were 
reported to be about 10% and 16% respectively (Scott et al., 2012). Patients were found to be 10%-
30% less likely to undergo medical examinations for CVD and to have a risk of inpatient mortality 
of 80%.  People with type 2 diabetes and SMD were over 60% less likely to receive all of six 
recommended measures (eye, lipid and foot sensory tests, and haemoglobin A1c, blood pressure and 
urine protein examinations) compared to controls. In the United Kingdom (UK), between 2003 and 
2005 patients with schizophrenia were 15% and 7% less likely to receive statins and have recorded 
cholesterol levels, while smoking counselling and blood pressure records were comparable to those 
of the general population (Scott et al., 2012). Diabetes care disparities in countries with universal 
health care, such as the UK, may be reduced, according to a population-based survey of general 
practice records, that found non differences in 17 quality indicators for diabetes care (Scott et al., 
2012). However, only 41% of antipsychotics users had received a prior blood glucose test and only 
19% and 4% had their weight recorded and lipids monitored (Scott et al., 2012). 
In addition, individuals with SMD may receive reduced attention to lifestyle assessment and 
education (Scott et al., 2012). 
Daumit et al. (2006) estimated the prevalence of adverse events in medical and surgical 
hospitalisations for persons with schizophrenia compared with those for persons without 
schizophrenia and found that medical and surgical hospitalisations for persons with schizophrenia 
had at least twice the odds of several types of adverse events than those for persons without 
schizophrenia. These adverse events were associated with poor clinical and economic outcomes 
during the hospital admission (Daumit et al., 2006). Possible explanations given by the authors for 
the phenomenon are: medical injury, undiagnosed medical comorbid disease, higher clinical 
severity or effects of smoking or antipsychotic medication. However, incorporating medical 
comorbid conditions into the regression models did not appreciably change the odds ratios for 
adverse events. This supports the assertion that the quality of care given to patients while 
hospitalized, and not principally the severity of medical conditions, was a true contributor to the 
increase in the odds (Daumit et al., 2006). 
Biological factors (Genetics/Neuroendocrine factors) 
Different biological explanations of the high physical comorbidity observed are under study. 
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Patients with psychiatric disorders are more likely to have abnormalities in glucose 
regulation (e.g., insulin resistance) and greater visceral adiposity than healthy individuals, even 
before the initiation of antipsychotic therapy (Allison et al., 2009; Megna et al., 2011). Baseline 
insulin resistance likely contributes to the development of type 2 diabetes mellitus and MS in 
general, as well as when these abnormalities evolve without significant weight gain (Megna et al., 
2011). In their study, Thakore et al. (2002) found significantly higher baseline plasma cortisol 
levels in patients with schizophrenia than in control subjects. Hypercortisolemia is known to have 
marked effects on the distribution of body fat in the abdominal area, therefore leading to abdominal 
obesity. 
There is a complex relation between genetic and environmental factors, which is not well 
understood as of now. Some authors suggest that genetic risk factors for type 2 diabetes also 
increase the risk of developing schizophrenia. Hansen et al. (2011) analysed the risk conferred by 
known type 2 diabetes susceptibility variants for developing schizophrenia and found one of the at-
risk alleles for type 2 diabetes to be associated with schizophrenia. Such findings could explain the 
physiological abnormalities found even in drugs-naïve patients. In effect, up to 30% of people with 
schizophrenia have a family history of type 2 diabetes (Holt et al., 2004). Genetic factors interact 
then with environmental factors (including antipsychotic drugs) to determine the set of physical 
comorbidities found in psychiatric patients. Low birth weight, for example, is considered to be 
related to the development of both type 2 diabetes and schizophrenia (Holt et al., 2004). 
The role of neuroendocrine factors such as leptin, ghrelin, orexins, and prolactin is being 
investigated too, but at the moment it remains unclear (Megna et al., 2011). 
 
2.4 Intervention strategies 
Due to the involvement of both pharmacological and non-pharmacological risk factors in the 
development of physical health issues in psychiatric patients, similarly, both pharmacological and 
non-pharmacological interventions have been developed to target these issues. 
 
Pharmacological interventions 
Choice of antipsychotic medication 
If a patient has a personal or family history of obesity, diabetes, hyperlipidemia or 
hypertension, selection of an agent associated with less weight gain would be prudent (Megna et al., 
2011). If more than 7% of baseline body weight is gained, switching to an antipsychotic medication 
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with lower weight gain liability must be considered (Megna et al., 2011). Also, according to a 
Consensus Development Conference led by the ADA, switching antipsychotic medication should be 
considered for patients who develop worsening glycaemia or dyslipidemia (ADA, 2004). Even 
according to the systematic review by Faulkner et al. (2007), the first strategy in preventing or 
alleviating weight gain remains identifying an appropriate choice of antipsychotic which has a 
lower liability of weight gain. 
Pharmacologic therapies 
The extensive systematic review published by Faulkner et al. (2007) examined both 
pharmacological and non-pharmacological interventions for weight reduction in schizophrenia. 
Pooled results for studies on pharmacological prevention or intervention are reported in Figure 1 
and 2 and in Table 3. On a whole, pharmacological interventions showed some efficacy in 
achieving modest weight loss. However, there is marked heterogeneity across studies and according 
to the authors at this stage there is insufficient evidence to support pharmacological interventions 
for weight loss in this population (Faulkner et al., 2007). A more recent systematic review and 
meta-analysis (Maayan et al., 2010b) concluded that, for many individuals, the adjunctive 
pharmacological agents studied for weight management in antipsychotic-treated patients are 
unlikely to return the patients' weight to baseline. Nevertheless, the most robust results, even if 
modest and heterogeneous, were in favour of metformin (Maayan et al., 2010b). However, literature 
converges on recommending the association of lifestyle intervention with pharmacological 
treatment. 
Regarding diabetes, the ADA stated that the benefits and risks of different therapeutic agents 
used in the treatment of diabetes and its comorbidities should be considered in the context of the 
patient’s psychiatric condition and treatment (ADA, 2004). 
Analysing studies on smoking cessation and reduction, Tsoi, Porwal and Webster (2010) 
found bupropion to be effective in smoking cessation, as well as smoking reduction. However, the 
strength of the evidence is relatively weak with wide confidence intervals, especially for longer 
term benefit. For other drug treatment and psychosocial interventions, they did not find sufficient 
and convincing evidence to support use in clinical practice (Tsoi et al., 2010). 
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Table 3 Efficacy of pharmacological interventions for weight management in schizophrenia (Faulkner et al., 
2007) 
TYPE OF INTERVENTION COMMENT RESULTS 
Prevention studies Treatment group Control group 
H2ANTAGONISTS versus PLACEBO No significant differences.   
H2 ANTAGONISTS -HIGHER DOSE 
versus H2 ANTAGONISTS - LOWER 
DOSE 
No significant differences.   
H2 ANTAGONISTS - HIGHER DOSE 
versus H2 ANTAGONISTS - LOWER 
DOSE 
No significant differences.   
5HT REUPTAKE BLOCKER versus 
PLACEBO 
No significant differences.   
SELECTIVE NOREPINEPHRINE 
REUPTAKE INHIBITOR versus 
PLACEBO 
BMI data were equivocal by 6 
weeks. BMI change scores by 6 
weeks favoured the treatment 
group. 
  
ANTIDIABETIC AGENTS versus 
PLACEBO 
No significant differences.   
ANTICONVULSANT AGENT versus 
CONTROL 
Treatment group had 
significantly smaller increases 
in weight than the control 
group. 
  
SSRI’s + LOW DOSE CLOZAPINE 
versus HIGH DOSE CLOZAPINE 
No significant differences in 
total body weight and BMI. 
Significantly fewer patients in 
the SSRI’s plus low dose 
clozapine increased their initial 
weight by 7%. 
  
Summary Treatment group had significantly less gain in weight than the control 
group. 
Treatment studies   
ANTI OBESITY AGENTS +/- 
LIFESTYLE MANAGEMENT versus 
PLACEBO +/- LIFESTYLE 
MANAGEMENT 
No significant differences in 
BMI change. Change in weight 
favoured treatment group in one 
of the studies but not in the 
other one. 
  
H2 ANTAGONISTS versus PLACEBO Total body weight and BMI 
were favoured in the treatment 
group. Results in change in 
weight and BMI were 
heterogeneous, individually 
each trail demonstrated 
significant reductions in the 
treatment groups. 
  
APPETITE SUPPRESSANT versus 
PLACEBO 
Total body weight was lower in 
the control group by 3 months. 
Medium term weight change 
data favoured the treatment 
group. 
  
5HT REUPTAKE BLOCKER versus 
PLACEBO 
No significant differences.   
ANTIPARKINSONIAN DRUG versus 
PLACEBO 
Treatment group had 




No significant differences.   
ANTICONVULSANTS HIGHER DOSE 
versus ANTICONVULSANTS LOWER 
DOSE 
Change in weight favoured 
higher dose anticonvulsants 
group. 
  
Summary Treatment group had significantly less gain in weight than the control 
group, but data contains significant heterogeneity. 
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Figure 1 Pooled results for pharmacological weight gain prevention studies (Faulkner et al., 2007) 
 
Figure 2 Pooled results for pharmacological weight reduction intervention studies (Faulkner et al., 2007) 
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Non-pharmacological interventions 
Monitoring 
Specific guidelines for the management of physical health in patients treated with 
antipsychotics exist. Two of them have been developed by the Consensus Development Conference 
(ADA, 2004) and the Mount Sinai Conference (Marder et al., 2004). In 2006, the technical report 
by the USA NASMHPD recommends USA State Mental Health Authorities to embrace strategic 
approaches to reduce excess morbidity and premature death among this population (NASMHPD, 
2006). A consensus meeting held in the UK developed specific guidelines for the UK psychiatric 
population, based on the recommendations by the ADA (Barnett et al., 2007). 
According to ADA guidelines, patients taking antipsychotic medications, especially second 
generation antipsychotics, should receive appropriate baseline screening and ongoing monitoring 
(ADA, 2004). Baseline screening should include personal and family history of obesity, diabetes, 
dyslipidemia, hypertension or CVD; BMI; waist circumference; blood pressure; fasting plasma 
glucose; fasting lipid profile. Weight should be assessed every month for the first 3 months after 
initiating or changing second generation antipsychotic therapy and quarterly thereafter. Fasting 
glucose plasma, lipid levels and blood pressure should be assessed 3 months after the initiation of 
antipsychotic therapy and annually thereafter for those who have a higher baseline risk. 
According to the Mount Sinai Conference participants, weight should be monitored for all 
individuals with schizophrenia, using BMI as the most widely accepted measure standard (Marder 
et al., 2004). Monitoring should take place before antipsychotic medication initiation or change and 
at every visit for the first 6 months. When the weight stabilises, the patient should be weighed at 
least quarterly, or more often if the patient is overweight. A weight gain of one BMI unit indicates a 
need for an intervention. To this end, a family history of obesity or diabetes should further raise the 
clinician’s and patient’s awareness of potential health risks of weight gain (Marder et al., 2004).  A 
baseline measure of plasma glucose level should be collected for all patients before starting a new 
antipsychotic. Patients who are gaining weight should have their fasting plasma glucose level or 
haemoglobin A1C monitored every 4 months. Patients who have significant risk factors for diabetes 
should have these values monitored 4 months after starting an antipsychotic and then yearly 
(Marder et al., 2004). Mental health providers should also be aware of the lipid profile of each 
patient with schizophrenia they treat (Marder et al., 2004). The profile should include measurements 
of total, LDL and HDL cholesterol and triglycerides levels. Then lipid screening should be carried 
out at least once every 2 years when the LDL level is normal and once every 6 months when the 
LDL level is greater than 130 mg/dl. In this case, the patient should be referred to a primary care 
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provider or internist or advised to change his/her diet. Antipsychotics associated with 
electrocardiogram (ECG) abnormalities should not be prescribed for patients with known heart 
disease, history of syncope, family history of early sudden death or congenital long QT syndrome. 
According to the UK consensus meeting, initial evaluation should ideally include a complete 
medical history, measurement of weight and height, waist circumference, blood pressure/pulse, and 
glucose and lipid levels (Barnett et al., 2007). The introduction of a regular routine monitoring in 
patients receiving antipsychotics is recommended to allow the early detection of metabolic side 
effects. BMI should be monitored every 4 weeks during the first year of antipsychotic therapy. 
Blood pressure, fasting plasma glucose and lipid profile should be monitored after 12 weeks since 
the beginning of antipsychotic therapy. Each parameter should then be monitored 6-monthly. The 
different weight gain liabilities of antipsychotic medications should be taken into account when 
choosing or switching pharmacological treatment for a patient. 
Tarricone and colleagues (2006), based on the results of their study on an Italian sample, 
recommend  monitoring of weight, fasting plasma glucose, cholesterol and triglyceride levels, in 
accordance with international guidelines, when prescribing antipsychotics. The monitoring of 
specific health parameters should lead to appropriate interventions if any abnormality is observed, 
whether the intervention be strict monitoring, antipsychotic medication switching, health behaviours 
improvement or pharmacological interventions (antihypertensive or anticholesterol medication etc.). 
This is especially true in view of the unhealthy lifestyles and self-neglect of psychiatric patients, 
that expose them to a greater extent to the complications of overweight and obesity (Tridente et al., 
2005). 
Lifestyle interventions 
Scientific literature has examined the topic thoroughly, with reviews covering a vast number 
of different intervention types or a specific type. The aim of "lifestyle interventions" is both to 
promote health, hence help psychiatric patients to develop healthier lifestyles, and to reduce risk 
factors. Promotion, broadly speaking, is intended as the provision of information and 
encouragement to people in the hope that they will act to avoid deterioration of current health or 
development of future health problems (Tosh, Clifton, Mala and Bachner, 2010). The goals of 
health promotion are (1) promoting positive health, (2) primary prevention and risk reduction, (3) 
secondary prevention, early detection and early treatment of diseases, and (4) tertiary prevention, 
care for patients with chronic or acute diseases (Kok, van den Borne and Mullen, 1997). Some of 
the interventions used in lifestyle programmes include manualised intervention programmes, 
psychoeducational interventions and health education in general and behavioural modification 
programmes (contingency management). Health education can be defined as any combination of 
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learning experiences designed to facilitate voluntary behaviour conducive to health (Kok et al., 
1997). Such strategies, in the context of lifestyle interventions, can be used in association or not 
with pharmacological therapies. This literature area is flawed by the lack of big and 
methodologically appropriate RCTs and, generally, by the heterogeneity of the interventions, targets 
of intervention, outcome measures and methods used. Bradshaw and colleagues (2005) reviewed 
literature on smoking cessation, weight management, exercise and nutritional education and 
highlighted that the general quality of studies reviewed was poor. Studies on smoking cessation, 
except one, provided group or individual treatment and adjunctive pharmacological treatment 
(nicotine replacement or bupropione). The results reported some reduction in cigarette use and 
cessation rates from 35% to 50% at the end of treatment, though the effect is reduced after 6 
months. In two of the three exercise studies reviewed, participants showed improvements in aerobic 
fitness. Results in the nutritional education studies were inconsistent. Only 7 of 16 studies achieved 
a score for methodological quality of 50% or above and these were only studies on smoking 
cessation and weight management. No study was longer than 6 months (Bradshaw et al., 2005). 
As previously mentioned, the systematic review and meta-analysis by Tsoi et al. (2010) 
failed to find convincing evidence that interventions differing from bupropion have a beneficial 
effect on smoking behaviour in schizophrenia. Abstinence rates reported in the studies are 
disappointing relative to the abstinence rates found in RCTs of smokers in the general population 
(Steinberg and Williams, 2007). McChargue, Gulliver and Hitsman (2002), however, point out that 
some evidence shows decreases in the biomarkers associated with smoking harm in smoking 
reduction trials, leading to consider the potential use of reduction approaches in schizophrenic 
smokers, rather than abstinence approaches. 
Regarding weight management interventions, it is renown that, in the general population, 
self-directed and commercial lifestyle-modification programs induce reductions of up to 5% from 
initial weight, while clinical programs induce mean reductions of 7%-10% and produce significant 
improvements in metabolic indices and quality of life (Allison et al., 2009). RCTs (randomised 
controlled trials) comparing lifestyle modification with treatment as usual in patients with mental 
illness are few and methodologically varied (Allison et al., 2009). According to our systematic 
review of recent literature on non-pharmacological weight management interventions, pooled 
results for all the studies show a weighted mean difference between experimental group and control 
group in BMI of −0.98 kg/m2, in favour of the experimental group (Bonfioli et al., 2012; Figure 3). 
Recently, Daumit and colleagues (2013) studied the effectiveness of an 18-month tailored 
behavioural weight-loss intervention in adults with SMD. The intervention focused on weight loss 
in overweight or obese individuals, providing group and individual weight-management sessions 
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and group exercise sessions. At 18 months, the mean between-group difference in weight (change in 
intervention group minus change in control group) was −3.2 kg. About 37% of the experimental 
subjects lost 5% or more of their initial weight, as compared with 22% of control subjects (Daumit 
et al., 2013). The specific target of this intervention was to reduce caloric intake. Yet, the role of 
physical inactivity and poor diet as independent risk factors for CVD infers the need for non 
pharmacological or lifestyle intervention regardless of weight loss per se (Faulkner et al., 2007). In 
fact, the authors state that the amount of weight loss, albeit modest, compares favourably with 
weight loss in lifestyle interventions trials in the general population and has been shown to have 
beneficial effects such as reduced risk of CVD and diabetes (Daumit et al., 2013). Early 
interventions should be promoted shortly after initiation of antipsychotic therapy because this helps 




Figure 3 Efficacy of lifestyle interventions (Experimental) vs. treatment as usual (Control) for weight 





Psychiatric patients have major barriers in accessing medical care, therefore risk factors like 
obesity, hyperglycaemia and hypertension are under-recognised and under-treated (Amiel et al., 
2008). Improved therapeutic methods with more substantial containment of weight gain are needed, 
ideally before the associated morbidity is manifest (Megna et al., 2011). As a whole, future research 
needs: 
 better understanding of the mechanisms involved; 
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 investigating earlier interventions; 
 adequately powered RCTs of sufficient duration; 
 further studies comparing the relative contribution of nutrition counselling and physical 
training; 
 investigating how to best adapt lifestyle interventions to the motivational, cognitive, 
social and resource deficits often observed in psychiatric patients (Allison et al., 2009). 
The evidence suggests that for example weight management programmes similar to those 
used in the general population are worthy of further research using large numbers of participants 
randomly allocated (Bradshaw et al., 2005). 
For all these reasons, we decided to design a randomised study that could fill the 
insufficiency of literature and offer new insights in this area. 
 




The rationale for this study is to provide further insights on the efficacy of health promotion 
interventions for patients with SMD, given the extensive evidence in literature on the higher 
physical comorbidity and mortality experienced by these patients and on the necessity of further 
clinical trials in this area. 
The general objective of the study reported here is to implement health promotion strategies 
on diet and physical exercise in psychotic patients and to study their efficacy. Specific objectives 
are to finalise the intervention package; to conduct the preventive intervention and monitor the 
attendance and relevant habits of participants; to assess the participants at baseline and at the end of 
intervention as to dietary habits, physical exercise and health status. 
The main hypothesis of the study is that the PHYSICO-DSM-VR intervention (described in 
the "Intervention" section) will result in the improvement of physical activity and diet-related 
behaviours in people with functional psychoses, compared to those receiving treatment as usual. 
Secondary hypotheses are the improvement of examined physical health parameters, health-related 




The study is a randomised controlled trial, comparing a health promotion package to 
treatment as usual. The process of identifying participants and obtaining consent to randomisation is 
described in Figure 4 according to CONSORT guidelines (Schulz, Altman & Moher, 2010). 
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Eligible patients were identified by means of the local Psychiatric Case Register (PCR; 
Amaddeo et al., 1997) or referred by psychiatrists, according to the criteria described hereinafter. 
Patients were included after giving written consent.  
Inclusion criteria 
 ICD-10 diagnosis of affective or non-affective functional psychosis (codes F20-22, F24-
F25, F28-F31, F23.3, F33.3); 
 age 18-65; 
Assessed for eligibility (n=  ) 
Excluded  (n=   ) 
♦   Not meeting inclusion criteria (n=  ) 
♦   Declined to participate (n=  ) 
♦   Other reasons (n=  ) 
Analysed  (n=  ) 
♦ Excluded from analysis (give reasons) (n=  ) 
Lost to follow-up (give reasons) (n=  ) 
Allocated to intervention (n=  ) 
♦ Received allocated intervention (n=  ) 
♦ Did not receive allocated intervention (give 
reasons) (n=  ) 
Lost to follow-up (give reasons) (n=  ) 
Allocated to intervention (n=  ) 
♦ Received allocated intervention (n=  ) 
♦ Did not receive allocated intervention (give 
reasons) (n=  ) 
Analysed  (n=  ) 





Randomized (n=  ) 
Enrollment 
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 one or more contacts with the Community Psychiatric Service (CPS) in the 3 months 
preceding the beginning of the recruitment. 
Exclusion criteria 
 moderate or severe mental handicap; 
 organic brain disorders; 
 lack of capacity to consent to inclusion; 
 subjects already involved in individual treatment related to diet and physical exercise; 
 subjects deemed unable or unfit to participate in the proposed physical activities. 
Setting 
The project includes the four CPSs of the Department of Mental Health of the ULSS 20 
(Unità Locale Socio-Sanitaria, Verona). The duration of the project is from October 2011 to March 
2014. Total catchment area includes a population of about 500.000 residents and it extends over the 




The experimental group received treatment as usual for the psychiatric disorder plus a health 
promotion intervention package. The intervention package (6 months duration) consists in: 
 7 1-hour health education group sessions for patients, two on physical activity and 5 on 
nutrition, provided by two trainers and two dieticians; 
 weekly group walking sessions under the guide of an expert trainer; 
 motivational interviewing to promote adherence; 
 an educational session for mental health workers involved. 
The project staff is composed by three researchers for the Coordinating Research Centre, 
four researchers (psychologists; one for each of the centres in which the study took place), two 
dieticians and two trainers (each working on two centres). 
The training phase of the project and the preparation of materials for the assessment and 
intervention phases began in January 2012, with bi-weekly staff meetings and including 3 training 
sessions on both nutrition and physical activity promotion provided by staff from the Department of 
Prevention (ULSS 20). The training provided by the Department of Prevention helped in the 
creation of the materials used by the dieticians and trainers with patients and mental health workers 
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during the intervention phase (see Appendix 3). For the intervention, subjects were divided in small 
groups of about 10 persons with staggered starts. 
Control group 




The primary outcome is based on WHO recommendations on diet and exercise (WHO, 
Global Strategy on Diet, Physical Activity and Health), in particular: 1) Take 5: at least five 
servings of fruit and/or vegetables a day (400-500 grams daily); 2) engaging in moderate physical 
activity (like brisk walking) for at least 30 minutes on at least 5 days a week. The improvement of at 
least one WHO recommendation (5 servings of fruit and/or vegetables per day and/or amount of 
moderate physical activity as specified above) at the final assessment compared to the initial one 
will be considered a successful change. Secondary outcomes are the measures of health status, 
quality of life related to health and satisfaction. 
The time points of primary interest are baseline and follow-up. 
Assessment 
Assessment instruments 
Experimental and control subjects were tested at baseline and after the end of treatment 
(follow-up) with the instruments and parameters described below. The assessment of participants of 
both experimental and control group was also performed at monthly intervals for the duration of the 
intervention period, according to the schedule shown in Table 4. 
1. SCAN-IGC: Confirmation of diagnosis (Schedule for Clinical Assessment in 
Neuropsychiatry; Wing et al., 1990); 
2. CSSRI-EU: Socio-demographical data (Client Sociodemographic and Service Receipt 
Inventory ; Chisholm et al., 2000); 
3. Physical health assessment: 
a. physical examination; 
b. heart rate and blood pressure; 
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c. MOD.ISTAT/IMF-8/B.04-05-ISTAT (item 2.1-2.24): a questionnaire on chronic 
illnesses taken from an instrument developed by the National Institute of Statistics for a 
survey on Italian families health (ISTAT, 2004); 
d. BMI and abdominal circumference; 
e. laboratory tests: 
i. fasting blood glucose and haemoglobin A1C; 
ii. LDL and HDL cholesterol, triglycerides; 
iii. plasma parameters log (TG/HDL-C); 
iv. vitamin D; 
f. ECG; 
g. total body Dual-energy X-ray Absorptiometry (DXA) (only for a subgroup of 
subjects); 
h. medication history; 
i. CUORE: cardiovascular risk score. The CUORE individual risk score is a tool for 
assessing the probability of developing a first major cardiovascular event (myocardial 
infarction or stroke) over the following 10 years, when the values of eight risk factors are 
known: gender, age, diabetes, smoking habit, systolic blood pressure, serum cholesterol, 
HDL cholesterol and the prescription of anti-hypertensive medications (Palmieri et al., 2004; 
www.cuore.iss.it). It is applicable in people from age 35 to age 69; 
4. PASSI: questionnaire on physical activity and diet habits. PASSI is a questionnaire used 
in the context of an epidemiologic study on the monitoring of health habits and illness risk 
(Progressi delle Aziende Sanitarie per la Salute in Italia, 2005) and including data on physical 
activity and eating habits; 
5. SF-36: questionnaire on health-related quality of life (Medical Outcome Study - MOS - 
36 Item Short Form Health Survey; Ware et al., 1992); 
6. VSSS-EU: questionnaire on patients satisfaction with the CPS (Verona Service 
Satisfaction Scale – European Version; Ruggeri et al., 2000); 
7. Walking Distance form: it collects with a pedometer number of steps performed by 
subjects of experimental group during the physical exercise sessions. 
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Table 4 Assessment instruments 
TIME ASSESSMENT VERSION 
Baseline assessment 1. SCAN-IGC 
2. Health status documentation form 
3. CSSRI-EU 






1. heart rate and blood pressure 
2. BMI and abdominal circumference 
3. PASSI questionnaire (short form) 
Final assessment 
(6 months) 
1. Health status documentation form (only blood tests, heart rate, blood 
pressure, BMI and abdominal circumference) 
2. CSSRI-EU  





We fixed a minimum adherence to treatment (in terms of percent participation in sessions) 
≥60%. Following this criterion we assume an attrition rate of 50% as acceptable in view of the 
considerable difficulty of this type of patients to attend interventions regularly overtime (Roberts & 
Bailey, 2011). 
We are well aware of the evidence (Rollnick et al., 2003) on the difficulty relative to all 
interventions to modify human behaviour and therefore set the minimum percentage of change in 
the endpoint to consider the intervention successful according to the aforementioned awareness. In 
order to estimate the sample sizes for two-group comparisons of ordinal outcomes, the conventional 
formula of Whitehead (1996) was performed, using a R software library and taking into account 
data presently available from Phase 1 of PHYSICO (Berti, 2010) on proportion of subjects 
satisfying one, two or no WHO recommendations (WHO, Global Strategy on Diet, Physical 
Activity and Health). Of 186 subjects analysed in Phase 1, 65.1% did not meet WHO criteria for 
diet and physical activity, 34.4% met only one criterion (Take 5 or physical activity) and 0.5% met 
both. Our hypothesis is that after the intervention our groups would be distributed as follows: 
 intervention group: 51% not meeting WHO criteria for diet and physical activity, 34% 
meeting only one criterion and 15% meeting both; 
 control group: 63% not meeting WHO criteria for diet and physical activity, 32% 
meeting only one criterion and 5% meeting both. 
We determined that to detect a 10-15% difference between two groups on satisfying at least 
one WHO criterion, with an α of 0.05, two sided testing, and a power of 0.80, we needed at least 
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175 subjects eligible (234 participant when the power was fixed to 0.90). However, taking potential 




Stratified randomisation was done by confounding variables (sex and age). The 
randomisation list was prepared by the method of blocks of randomized permutation. 
The randomisation lists was generated using Stata software, following the randomised 
permuted blocks (by center, age- class and gender of patients) criteria in order to guarantee 
balanced sub-samples. In more detail, the randomization sequence is conducted off-site using the 
“random allocation of treatments balanced in blocks (ralloc)” package for Stata (Ryan, 2008) and is 
stratified by centre, gender and age class with a 1:1 allocation ratio of treatment. Block 
randomization (size 3) is used to minimize large imbalances between the intervention groups. The 
allocation sequences were generated by an independent individual, are stored in computer files and 
remain unknown to the researchers until the patient is randomized. 
 
Statistical analyses 
Chi-square test for categorical data was performed in order to check the treatment effect in 
our primary outcome. Linear regression model has been used to analyse effects on partial outcomes 
regarding lifestyles (mean number of fruit/vegetables portions per day and mean number of minutes 
of physical activity per week).  
 
3.3 Results 
Implementation of the project 
In March 2012, the Phase 1 protocol amendment, which allowed the beginning of the trial, 
was approved by the ULSS 20 and the AOUI of Verona (Azienda Ospedaliera Universitaria 
Integrata di Verona) ethics committees. 
In April 2012 the recruitment of subjects began. The assessment process was completed 
with the collaboration of all the Departments involved (Unit of Cardiology and clinical laboratories 
of both AOUI and ULSS 20, Unit of Bone Densitometry of AOUI). The recruitment of subjects was 
carried out by representatives of the single CPSs in collaboration with psychiatrists. Once obtained 
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the informed consent by the subjects, the evaluators proceeded to carry out the assessment, 
including medical exams, measurements and interview, and psychiatrists proceeded to fill in the 
Health Status Documentation Forms for their patients.  
In October 2012 the intervention phase began in each of the four CPSs. During the 
intervention phase, a monthly assessment of experimental and control subjects has been carried out 
in a short form, through the measurement of heart rate, blood pressure, BMI and abdominal 
circumference and through the administration of a short form of the PASSI questionnaire. 
The feedback from participants has been good: especially those who attended more regularly 
showed much interest and curiosity about the topics covered in the educational sessions with the 
dieticians and participated actively. Also, with regard to the walking groups, the majority of patients 
showed motivation, noticed a greater wellness at the end of meetings and interacted with each other 
positively. Groups are starting to fit into the activities of the various Mental Health Centres, as an 
integral part of rehabilitation activities. Critical issues include the heterogeneity of the individual 
level of autonomy, the concentration skills and the interaction skills of the various participants; in 
addition, some of them were not attending sessions  with the required regularity. 
As of January 2014, the assessment procedure has been completed and as of February 2014 
data has been entered in the database and analysed. 
 
Participants 
A total of 844 subjects were identified as eligible in the period from April 2012 to June 2013 
(Figure 5). Patients were included after giving written informed consent (see Appendix 1). As of 
January 2014, 359 subjects have completed baseline assessment and have been randomized. Four 
hundred and eighty-five subjects were excluded, for refusing to participate (219), reasons related 
with psychopathology (158) or other reasons (108). The experimental group has included a total of 
180 subjects, of whom 143 received the intervention. Twenty-five subjects in the experimental 
group and 32 in the control group were lost to follow-up. Reasons for dropping out are: death, 
hospitalisation, moving, inability to contact patient, refusal of the patient to participate in follow-up 
assessment. 
Baseline demographic characteristics of the sample are shown in Table 6 and Figure 6. 
There are no significant differences at baseline between the experimental and the control group in 
these variables, therefore we can say that confounding variables act in the same way on the two 
groups (marital status: χ2(2) = 0.09, p = 0.96; living condition: χ
2
(2) = 0.27, p = 0.87; education: χ
2
(3) 
= 4.1, p = 0.25; working status: χ2(1) = 0.04, p = 0.85; psychiatric diagnoses: χ
2
(1) = 0.46, p = 0.5). 
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* reasons related to organic pathology = 25; difficulty of contact = 27; other reasons = 56 
**experimental group: never participated to intervention; control group: deceased, moving abroad 
***reasons: death, hospitalisation, moving, inability to contact patient, refusal to participate in follow-up assessment 
****subjects already fulfilling WHO criteria for diet and physical activity and subjects with missing outcome data at 
baseline (excluded from analyses on primary outcome) 
Assessed for eligibility (n= 844) 
Excluded  (n=  485) 
♦   Declined to participate (n= 219) 
♦   Reasons related to psychopathology 
(n= 158) 
♦   Other reasons (n= 108)* 
Analysed  (n= 175) 
♦ Excluded from analysis (n= 5)**** 
 
Lost to follow-up (n= 25)*** 
Allocated to experimental group (n= 180) 
♦ Received allocated intervention (n= 143) 
♦ Did not receive allocated intervention (n= 
37)** 
 
Lost to follow-up (n= 32)*** 
 
Allocated to control group (n= 179) 
♦ Received allocated intervention (n= 175) 
♦ Did not receive allocated intervention (n= 
4)** 
 
Analysed  (n= 170) 






Randomized (n= 359) 
Enrollment 
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Table 6 Socio-demographic and clinical characteristics of the sample by group, gender and total at baseline 
(n=353) 
n (%)  OR  mean (SD) 
Experimental Group  Control Group  
Socio-demographic and 
clinical characteristics 
Male Female Tot Male Female tot 
Gender 








Age years       (exp. gr. = 179; contr. gr. = 














Marital status                                                                                                                  



















Separated, divorced, widowed 
9 (10) 18 (20.93) 
27 
(15.34) 
5 (5.26) 23 (29.11) 
28 
(16.09) 


























19 (20) 9 (11.54) 
28 
(16.18) 
Education        (exp. gr. = 176; contr. gr. = 171)                                                                                                                      
Without a degree/Elementary 
school 
6 (6.59) 7 (8.24) 13 (7.39) 3 (3.23) 9 (11.54) 12 (7.02) 




















Other 1 (1.1) 0 (0) 1 (0.57) 1 (1. 08) 5 (6.41) 6 (3.51) 





















Psychiatric diagnoses*                                                                                                    
Schizophrenia and other 
functional psychoses (F20-F22, 
F23.3, F24-F25, F28-F29) 








Affective psychoses  (F30-F31, 





35 (42.68) 60 (33.9) 
* International Classification Diseases 10th revision (WHO, 2007) 
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Figure 6 Socio-demographic and clinical characteristics of the sample by group at baseline (n=353) 
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The number and type of physical diagnoses found in the sample is shown in Table 7 and in 
Figure 7. A total of 216 diagnoses have been found to be present or to have been present (in the 
previous 12 months or during lifetime) in the sample (91 in the experimental group and 125 in the 
control group). In the table, diagnoses have been grouped according to the corresponding ICD-10 
Chapters (ICD 10, WHO, 2007). Diseases of the nervous system and diseases of the circulatory 
system are the more represented in the sample (23.2% and 18.1% respectively), followed by 
endocrinal, nutritional and metabolic diseases (13.9%).  
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Table 7 Number of physical diagnoses (N =216) according to ICD-10 groupings and the corresponding ISTAT 
questionnaire items and percentage of subjects (N =190) per diagnosis, by gender and group at baseline  
ICD-10 Physical diagnoses* 
(n=190) 
Long-term chronic disease 
inventory items** 
n (%) 
Exp. Gr. Control Gr. ICD-10 Chapter (codes included) Physical diagnoses included 
M F tot M F tot 
II Neoplasm (C00-D48) malignant tumour  





III Diseases of the blood and blood- 
forming organs and certain 















IV Endocrinal, nutritional and 
metabolic diseases  (E00-E90) 












VI Diseases of the nervous system  ictus, cerebral haemorrhage, 
headache, chronic or recurrent 
migraine, Alzheimer, senile 
dementia, parkinsonism, other 























IX Diseases of the circulatory 
system 
hypertension, myocardial 


























XI Diseases of the digestive system 
XIV Diseases of the genitourinary 
system 
gastric or duodenal ulcer, liver 
or gall stones, kidney stone, 













XII Diseases of the skin and 
subcutaneous tissue 












XIII Diseases of the 
















* International Classification of Diseases 10th revision (WHO, 2007) 
** items from 2.1 to 2.24: MOD.ISTAT/IMF-8/B.04-05-(ISTAT, 2004) 
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Figure 7 Percentage of physical diagnosis according to ICD-10 groupings in the sample (n=190)  
Percentage of physical diagnosis according to ICD-10 











0% 5% 10% 15% 20% 25%
II      Neoplasms
III     Diseases of the blood and blood- forming organs and
certain disorders involving the immune mechanism
IV    Endocrinal, nutritional and metabolic diseases
VI    Diseases of the nervous system 
VII   Diseases of the eye and adnexa
IX    Diseases of the circulatory system
X     Diseases of the respiratory system
XI    Diseases of the digestive system  XIV  Diseases of
the genitourinary system
XII   Diseases of the skin and subcutaneous tissue





Health parameters, as measured by Health Status Documentation Form at baseline and 
follow-up, are shown in Table 8 and Figure 8 and 9. 
At baseline, 36.6% of the sample is overweight, 25.7% is moderately obese, 14.3% is 
severely obese and 2.3% is morbidly obese, resulting in 78.9% of the subjects being either 
overweight or obese. About 6% of the females is morbidly obese, compared to 2% of the males. 
The mean BMI is 30.46 (SD = 7.89) for females and 29.44 (SD = 5.33) for males. About 70% of the 
sample is at high risk according to ATP III criterion for abdominal circumference (62.5% of males 
and 76.1% of females have abdominal obesity according to ATP III criterion). About 40% of the 
subjects have high blood pressure. Twenty-two percent have borderline QTc interval and 8.5% have 
a prolonged QTc interval. In the experimental group, around 80% of subjects are overweight or 
obese, 71.4% have a high abdominal circumference, 41% have high blood pressure, and 7.9% have 
a prolonged QTc interval. Mean pulse at baseline is 80.85 bpm (SD = 14.22). 
Plasma laboratory tests results are reported in Table 9 and Figure 10, divided by group and 
gender. At baseline, 6.5% of the sample has diabetes and 6.8% has pre-diabetes, as identified by 
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fasting plasma glucose level. The mean value is 99.33 mg/dl (SD = 29.27): 100.85 mg/dl (SD = 
31.28) for the experimental group and 97.71 mg/dl (SD = 26.96) for the control group. LDL 
cholesterol levels are high in 46.18% of the sample (>130 mg/dl). Mean LDL plasma cholesterol is 
129.78 mg/dl (SD = 36.35): 129.38 mg/dl for the experimental group (SD = 33.52) and 130.22 
mg/dl for the control group (SD = 39.32). HDL cholesterol levels are low in 56.66% of the sample 
(values under 40 mg/dl for males and 50 mg/dl for females are considered too low). Mean HDL 
plasma cholesterol for males is 42.1 mg/dl (SD = 11.79) and for females it is 52.66 mg/dl (SD = 
12.74). Triglycerides levels are high in 38.6% of subjects (>150 mg/dl). Mean triglycerides level is 
155.16 mg/dl (SD = 124.38): 156.32 mg/dl (SD = 141.74) for the experimental group and 153.92 
mg/dl (SD = 103.08) for the control group. Glycated haemoglobin (haemoglobin A1c) is out of 
normal range (20-38 nmol/mol) in 50.63% of the sample. Mean glycated haemoglobin is 41.51 
nmol/mol (SD = 22.26): 41.63 nmol/mol (SD = 22.52) for the experimental group and 41.38 
nmol/mol (SD = 22.04) for the control group. Finally, vitamin D is out of normal range (30-80 
ng/ml) in 80.77% of subjects. Mean vitamin D value is 21.98 ng/ml (SD = 12.44): 21.36 ng/mol 
(SD = 11.51) for the experimental group and 22.66 ng/mol (SD = 13.42) for the control group. 
Cardiovascular risk 
Data on cardiovascular risk has been analysed at baseline, using CUORE index score based 
on gender, age, diabetes, smoking habit, systolic blood pressure, serum cholesterol, HDL 
cholesterol and the prescription of anti-hypertensive medications, in subjects from age 35 to age 69, 
as described in "Assessment instruments" (Palmieri et al., 2004). The score was applicable in 
67.69% of our sample. At baseline about 43% of the subjects have a low risk of developing a first 
major cardiovascular event over the following 10 years; 24.51% have a moderate risk; 0.28% have 
a high risk. There are no differences between experimental and control group in this variable at 
baseline (χ2(3) = 3.49, p = 0.32). 
Metabolic syndrome 
Data on metabolic risk has been analysed at baseline, according to the criteria proposed by 
ATP-III, including waist circumference, blood pressure, HDL cholesterol, triglycerides and fasting 
glucose (Grundy et al., 2004; see Table 2). At baseline 30.64% of the subjects fulfil the criteria for 
MS; at follow-up 23.4% of the subjects fulfil the criteria. 
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Table 8 Health parameters by gender, age group and total at baseline and follow-up (n= 331) 
n (%)  OR  mean (SD) 
Experimental Group Control Group 
Baseline Follow-up Baseline Follow-up 
Health 
parameters 
(N baseline; N 
follow-up) M F tot M F tot M F tot M F tot 
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Figure 8 Health status at baseline (n=326)  





























Figure 9 BMI and waist circumference by gender at baseline (n=331) 
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Table 9 Plasma laboratory tests results by group, gender and total (N= 329 ) 
n (%)  OR  mean (SD) 
Experimental Group Control Group 
Baseline Follow-up Baseline Follow-up 
Blood 
measurements 
M F tot M F tot M F tot M F tot 
fasting plasma 
glucose level    
mean (SD) 
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Figure 10 Plasma laboratory tests results by gender at baseline (n= 329)  



































The situation observed at baseline regarding lifestyles (diet and physical activity as defined 
by WHO criteria and our primary outcome) is similar to what has been observed in Phase 1: 62.2% 
of the sample meets no criteria, 35.71% meets 1 criterion and 2.08% meets both criteria. 
With an α of 0.05, two sided testing, 40.57% (71/175) of subjects in the experimental group 
fulfil one criterion more at follow-up than at baseline, while 32.35% (55/170) subjects of the control 
group do (Table 10 and Figure 11). The difference between groups is not significant (χ2(1) = 2.51, p 
= 0.11). Subjects who fulfilled already two criteria at baseline were excluded from the analysis. 
About 47% of the experimental subjects were compliant with the intervention, having 
participated to more than 60% of sessions, about 13% of subjects were partially compliant (30-60% 
of sessions) and about 40% participated to less than 30% of sessions (Table 11 and Figure 12). 
Percentages divided by age group and gender show that subjects from age 18 to age 45 and females 
were less compliant compared to the older age group and males. In both cases subjects tended either 
to participate to more than 60% of sessions or to participate to less than 30% of sessions. 
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Table 10 Change in the number of WHO criteria fulfilled for diet* and physical activity** at follow-up 
Primary outcome 
N (%) Group 
No change Change P*** 
Experimental (n=175) 104 (59.43) 71 (40.57) 0.11 
Control (n=170) 115 (67.65) 55 (32.35) 0.11 
* diet:5 servings of fruit and/or vegetables per day 
** physical activity:at least 150 minutes of moderate physical activity during the week 
*** χ2(1) = 2.51, p = 0.11 
 
Figure 11 Number of subjects who increased WHO criteria fulfilled at follow-up by group (n=345) 



















Table 11 Compliance with the intervention in the experimental group (n = 110) 
Compliance n (%) 
variables 
Compliant* Partially compliant** Non compliant*** 
 Total 75 (47.47) 21 (13.29) 62 (39.24) 
Age group 18-45 31 (39.24) 13 (16.46) 35 (38.30) 
 46-65 44 (55.70) 8 (10.13) 27 (34.18) 
Gender Male 43 (51.81) 10 (12.05) 30 (36.14) 
 Female 32 (42.67) 11 (14.67) 32 (42.67) 
*compliant: participated to >60% of sessions 
**partially compliant: participated to 30%>60% of sessions 
***non compliant: participated to <30% of sessions 
 
 - 50 - 
Figure 12 Compliance with the intervention in the experimental group (n=158) 













Below will be reported data on the two different aspects of the intervention (diet and 
physical activity) separately. 
Diet 
A linear regression showed a statistically significant group effect on the mean number of 
fruits and/or vegetables portions taken per day for participants, defined as having participated to 
>60% of sessions on diet (ß = 0.28, p = 0.04) (Table 12). Therefore, belonging to the experimental 
group and participating to a sufficient number of sessions is associated with an increase in the 
number of servings of fruits and vegetables of 0.3 units.  
 
Table 12 Linear regression on number of fruits and/or vegetables portions per day at follow-up 
n. of fruits/vegetables portions per day at follow-up ß 95 % CI 
n. of fruits/vegetables portions per day at baseline 0.40* 0.32-0.48 
Experimental subjects - compliant** 0.28* 0.01-0.55 
constant 1.26* 1.03-1.49 
** compliant: participated to >60% of sessions on diet 
 
Physical activity 
A linear regression showed a statistically significant group effect on the mean number of 
minutes of moderate physical activity per week for participants, defined as having participated to 
>60% of physical activity sessions (ß = 80.98, p = 0.001) (Table 13). Therefore, belonging to the 
experimental group and participating to a sufficient number of sessions is associated with an 
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increase in the mean number of minutes of moderate physical activity of about 80 minutes per 
week. 
 
Table 13 Linear regression on number of minutes of moderate physical activity per week at follow-up 
n. of minutes of moderate physical activity per 
week at follow-up 
ß 95 % CI 
n. of minutes of moderate physical activity per week 
at baseline 
0.29* 0.19-0.39 
Experimental group - compliant** 80.98* 33.87-128.08 
constant 90.01* 65.23-114.79 
** compliant: participated to >60% of sessions on physical activity 
 
Secondary outcomes 
At present data on secondary outcome has yet to be analysed. 
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IV. Discussion 
 
We have analysed only data regarding main time points (namely baseline and follow-up), 
however data on intermediate time points is available too. Results show that there is no statistically 
significant difference in the improvement in lifestyles as a whole in the experimental group 
compared to the control group, as defined by our primary outcome. Taking into account the 
participation to diet sessions and physical activity sessions separately, on those who participated, 
the intervention turns out to be effective on the single components of lifestyle. Patients who 
participated in at least 60% of the sessions on diet increased their mean number of fruits/vegetable 
portions per day by 0.3 units, starting from a mean of 1.9 portions per day (namely less than the 5 
portions recommended by WHO). Patients who participated in at least 60% of the sessions on 
physical activity, on the other hand, increased their mean number of minutes of moderate physical 
activity per week by about 80 minutes, starting from a mean of 142 minutes per week (namely less 
than the 150 minutes recommended by WHO), hence going in the direction recommended by WHO 
for a healthy lifestyle and the prevention of physical illness.  
The pattern of physical comorbidity found in the subset of the sample is similar to that 
identified in Phase 1, with diseases of nervous system, circulatory system, and endocrinal, 
nutritional and metabolic diseases among the more represented categories. Almost 80% of the 
sample is overweight or obese: even more than in phase 1 (68.2%). Waist circumference is over the 
recommended measures in 70%, similarly to phase 1 (68%). About 40% of our sample has high 
blood pressure compared to about 24% in phase 1 and about 8% show QTc prolongation similarly 
to phase 1 (about 7%). LDL cholesterol is out of range in 46.2% of our sample, compared to the 
35.1% of phase 1. HDL cholesterol is out of range in 56.6% of our sample, compared to 37% of 
phase 1. Triglycerides levels are high in about 38% of our sample and 43% of subjects in phase 1. 
Diabetes and pre-diabetes rates seem in part different (13.2% vs. 21.7%). These data are in line with 
what reported in the literature, as described in the Introduction. Obviously, it is not an objective of 
this study to explain the poor physical health of psychotic patients and possible mechanisms leading 
to it. 
In conclusion, it is rather difficult to influence dietary and physical activity habits in the 
general population and it is even more difficult in psychiatric patients, who might need a much 
more intensive intervention, perhaps including a personalised nutrition plan in the case of diet. Even 
when the compromised cognitive abilities and social skills of psychiatric patients are taken into 
account when delivering educational and psychological interventions, such strategies may not be 
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sufficient. The reason could be related to the fact that, to date, tailored interventions for psychiatric 
patients are still mostly based on clinical experience rather than on research data. Moderate physical 
activity, such as walking, seems to be more within range of a health promotion intervention like this 
and of these patients. Some of these patients do actually walk often, for reasons related to 
psychiatric symptoms (delusions or incompetences) or for necessity reasons (poverty) as a mean of 
transportation, but this is a minor percentage compared to the whole population. At baseline the 
mean number of minutes of moderate physical activity per week was about 140, namely under the 
30 minutes for 5 days a week recommended by WHO. Furthermore, results from phase 1 showed 
that a higher proportion of the clinical sample, compared to the general population of Veneto, was 
sedentary (no physical activity at all) vs. partially active (some physical activity, but less then 
recommended). It will be possible to investigate the same aspect in our sample. Nonetheless, 
similarly to the general population of Veneto region, about 66% of the subjects are either sedentary 
or partially active at baseline. Consequently, it is really important to improve physical activity 
levels in this population, especially given the higher risk of morbidity they bear. 
Available studies on this kind of interventions are typically insufficiently powered and 
poorly designed (Roberts & Bailey, 2011). As underlined by Bradshaw et al. (2005) in their review 
of lifestyle interventions, the evidence base for the efficacy of this kind of interventions in 
psychiatric populations is weak, largely because of the poor quality of the studies. In the last years, 
only one study with an adequate sample size and power calculation has been published (Daumit et 
al., 2013). The present study responds to the need of more adequate sample sizes and of a power 
calculation prior to conducting RCTs. It also draws attention to the fact that, as mentioned by 
Bernardo et al. (2009), it is important for healthcare professionals to work in an integrated manner 
when managing SMD patients, in order to optimise their treatment in relation to their general state 
of health. This is due to the substantial morbidity, seen in our sample too, and to the difficulties in 
accessing primary care of this population, as well as to aspects related to mental illness itself. 
This trial has used a different measure of outcome from other studies, based on WHO 
recommendations for diet and physical activity, therefore it is difficult to compare primary outcome 
results to other studies in literature. Most studies in this field are based on measures such as weight, 
physical fitness or physiological parameters. However, this is the first RCT in this field conducted 
in Italy to have an adequate sample size and comparing the contribution of diet education and 
physical activity in lifestyle change. Also, as mentioned by Faulkner et al. (2007) in their systematic 
review as an important aspect, we report multiple measures such as waist circumference, percentage 
of body fat, waist-to-hip ratio, adherence to dietary and physical activity components of lifestyle 
interventions and the related behavioural change. 
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In the light of the results of the regressions and data on participation, it seems quite 
reasonable to conclude that the principal issue is actually engaging this kind of population in a 
lifestyle intervention. Once engaged they can benefit from it, although to reach a significant change 
an intervention of this kind is not sufficient. A longer time period could be necessary to achieve a 
significant change. Motivation can obviously be a big issue for the general population too, but even 
more for psychotic patients, due to negative symptomatology and the substantial issues they face as 
a result of their psychopathology. In fact, as reported by Roberts & Bailey (2011), a limitation of 
this kind of approach is the problematic level of adherence to interventions in this group of patients. 
Barriers to engaging people with SMD to a lifestyle intervention seem largely related to illness, 
symptoms, and treatment with antipsychotic medication (Roberts & Bailey, 2011). According to the 
review by Roberts and Bailey (2011), cognitive limitations, poor motivation, decreased social 
interactions, lack of initiative and sedation are all reported as barriers for participation in studies 
regarding lifestyle interventions in SMD patients. Self-neglect, low self-esteem, appetite 
disturbance, financial issues and stigma may contribute too. The authors identified also possible 
incentives to participation, in particular contingency management, staff participation and peer 
support. Thus, in interpreting the results of the study it is important to take into account the fact that 
little less of half of the experimental subjects did not participate or participated only partially to the 
intervention. However, this also means that more than half of the sample had a rather good 
participation (considering the weekly sessions and the difficulties of transport that many patients 
have in reaching the CPS, especially in the 4th CPS area). Another limitation could be the duration 
of the intervention: even though the change is in the direction we expected, it might not be big 
enough to determine substantial and sustained changes in lifestyles and consequently in physical 
health parameters. Other possible limitations of the study and of this dissertation include: 
 blinding: participants and intervention staff blinding is impossible due to the nature of 
the intervention. Blinding of mental health workers employed in the Community Mental 
Health Centres where the study has taken place was also very difficult to achieve. 
Blinding of assessors should be sought when possible, because of the possible bias 
introduced by the knowledge of the experimental arm in the collection of data, and this 
was not the case for practical reasons; 
 psychiatric status of patients, in terms of quality and severity of symptoms, has not been 
assessed (albeit data is available in the PCR); 
 missing data: containment of missing data has not always been possible, due to various 
circumstances (missing data from clinical laboratories, inability to contact patients, etc.); 
 recruitment and assessment of subjects took a long period due to logistical issues; 
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 for reasons related to the aforementioned delays, only part of the data could be utilised 
and analysed as of now; 
The intervention was designed trying to bear in mind every aspect that could support 
generalisability of results to the real context of services. The proportion of subjects who accepted to 
participate on the total of contacted subjects was about 43%, versus 26% who refused to participate. 
This means that there is a good proportion of patients who accepted, demonstrating a good 
acceptability from the participants' point of view. Actually, a number of subjects randomised to the 
control group were eager to participate to the intervention and so were disappointed of not being 
able to participate. In some cases, the walking groups continued even after the end of the study, 
either autonomously or with help from mental health workers of the CPSs involved. Thus, the study 
supports the idea (as mentioned in Roberts and Bailey, 2011) that peer and staff support and regular 
group format are key factors in the delivering of lifestyle interventions for psychiatric patients. This 
is especially true in view of the difficulties of adherence above mentioned. Different CPSs have 
been involved in a vast territory, with similar and satisfactory results from an empirical point of 
view, meaning that it is not unlikely to implement a lifestyle intervention in different psychiatric 
healthcare settings. 
For future research, it is fundamental to design accurately the study protocol and 
intervention and to apply very rigorous research methods, from randomisation to enrolment, from 
assessment to data collection, to the delivering of the intervention. An additional important aspect to 
consider should be the psychiatric status of participants in terms of severity and quality of 
symptoms, which could influence the reception and efficacy of the intervention. 
Nevertheless, given the poor health status and unhealthy lifestyles so widespread in the 
psychiatric population (confirmed by our data), the focus on physical health promotion for this 
population remains an essential topic for any subject involved in psychiatric care, one that cannot be 
underestimated both from a research and a clinical point of view and that cannot be stressed 
enough. 
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V. Conclusions 
 
The objectives of Phase 1 and 2 of this study were to expand the knowledge on the 
prevalence of physical illness and unhealthy behaviours and to test an intervention programme to 
improve diet and physical exercise in patients with functional psychoses referred to the 4 CPSs of 
ULSS 20. In phase 2 we adopted a health promotion intervention for both diet and physical activity, 
with walking sessions for the latter, and measured health habits with questionnaires and health 
parameters with medical examination. 
Results confirm the alarming situation reported by previous literature regarding the 
increased risk factors, physical morbidity and mortality of psychiatric patients. The intervention 
package, as a whole, did not demonstrate having a significant impact on both health habits of the 
participants. Results on specific aspects of the intervention revealed a significant difference in diet 
and physical activity habits in subjects who participated to a sufficient number of sessions. 
Especially for what concerns walking groups, they could and should be usefully translated into 
rehabilitation practices of the centres. As stressed by Daumit et al. (2013), psychiatric rehabilitation 
programmes could be a useful setting, because they are often affiliated with outpatient clinics and 
therefore could serve as a hub for this kind of lifestyle interventions. Actually, we have already 
organised ad hoc meetings with the mental health workers in all CPSs to promote the continuation 
of the walking groups, which in some cases actually happened, with positive results. On the other 
hand, improving diet habits seems to be a more difficult objective and we are planning a more 
structured intervention programme with our partner, the Department of Prevention. Educational 
materials can also be made available to community mental health teams to assist them in assuming 
and maintaining responsibility as to the lifestyles of their patients. In fact, a composite package of 
interventions to promote multiple interventions for different lifestyles is of high clinical relevance 
and much needed by mental health community programmes. We are planning further research with 
an improved intervention package and with refined methods in order to identify a composite 
outcome measure of changes in health behaviours. 
Even though this group of patients is well followed by CPSs, there is still much to do to 
achieve adequate standards of detection, monitoring and treatment of physical health, besides 
mental health. More research is also needed to develop more efficacious interventions as well as to 
evaluate their cost-effectiveness. 
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Appendices 
Appendix 1 - Informed consent and ethical approval 
DICHIARAZIONE DI CONSENSO INFORMATO - PAZIENTE 
 





Io sottoscritto    ____________________________________   
nato a _______________________________ il____________________________ 




di accettare la proposta di partecipare alla SECONDA FASE dello studio PHYSICO- Physical co-morbidity, 
poor health behaviour and health promotion in Verona patients with functional psychoses: a 
Prevalence Study and a Randomised Controlled Study. Lo studio ha ricevuto l’approvazione del 
Comitato Etico della Provincia di Verona e del Comitato Etico dell’Azienda Ospedaliera Universitaria 
Integrata. 
 
Sono stato/a adeguatamente informato/a circa gli scopi dello studio e le metodiche dello stesso e ho ricevuto 
esaurienti spiegazioni in merito alla richiesta di partecipazione al progetto, secondo quanto riportato nella 
scheda informativa qui allegata, copia della quale mi è stata consegnata con sufficiente anticipo. 
  
Dichiaro altresì di aver potuto discutere tali spiegazioni, di aver posto tutte le domande che ho ritenuto 
necessarie e di aver ricevuto risposte soddisfacenti, come pure di aver avuto la possibilità di informarmi in 
merito ai particolari del progetto con persona di mia fiducia. 
  
Sono consapevole che potrò ritirarmi in qualsiasi momento dallo studio, senza obbligo da parte mia di 
motivare la decisione, ed esigere in ogni caso che il Servizio continui a garantirmi, con la dovuta attenzione, 
tutta l’assistenza sanitaria di cui ho bisogno.  
 
Dichiaro che il mio consenso è espressione di una libera decisione, non influenzata da promesse di denaro o 
altri benefici, né da obblighi di gratitudine o di amicizia e/o parentela nei confronti di partecipanti al gruppo di 
ricerca. 
 
Acconsento/non acconsento che le notizie riguardanti lo studio, limitatamente a quelle che potrebbero 
rivelarsi utili ai fini della mia salute, vengano trasmesse al mio medico curante, dott. ______________ 
 
Autorizzo sin d’ora l’utilizzo e la divulgazione, in forma anonima e per sole finalità scientifiche e 
amministrative e nell’osservanza delle vigenti norme sulla tutela della riservatezza, dei risultati della ricerca, 
compresi i dati clinici che mi riguardano. 
 
Firma    _____________________                                                 L’intervistatore  _____________________ 
 
  _____________________ 
          (Nome in stampatello) 
 
[Se il paziente non è in grado di leggere o di firmare, un testimone indipendente dallo staff dello studio deve essere 
presente durante l'intera discussione relativa al consenso informato. Il testimone deve firmare e datare personalmente la 
dichiarazione di consenso informato dopo che il modulo stesso e qualsiasi altra informazione scritta siano stati letti e 
spiegati al soggetto e questi abbia espresso il consenso verbale alla partecipazione allo studio]. 
 
In questo caso: 
                            Testimone _____________________ 
 
 _____________________ 
          (Nome in stampatello) 
  ii 
INFORMAZIONI PER IL PAZIENTE 






nell’ambito dello studio PHYSICO- Physical co-morbidity, poor health behaviour and health promotion in 
South Verona patients with functional psychoses: a Prevalence Study and a Randomised Controlled Study 
(PHYSICO- Comorbilità fisica, comportamenti a rischio e promozione della salute in pazienti con psicosi 
funzionale a Verona: studio di prevalenza e studio controllato randomizzato) sulla malattia fisica e la 
promozione della salute, la cui prima fase si è conclusa nel 2009 presso il 3° Servizio Psichiatrico, le 
proponiamo di collaborare alla seconda parte del progetto che si assocerà alla terapia farmacologica e agli 
interventi prescritti dal suo medico, inclusa la eventuale frequenza ad attività del Centro di Salute Mentale. A 
questo studio parteciperanno e saranno seguite persone, che come lei, sono  seguite dal nostro Servizio. Lo 
studio ha ricevuto l’approvazione del Comitato Etico della Provincia di Verona e del Comitato Etico 
dell’Azienda Ospedaliera Universitaria Integrata. 
 
Questa seconda fase si propone di confrontare un intervento di monitoraggio della salute fisica e di 
promozione della salute con il trattamento abituale presso il Servizio Psichiatrico Territoriale.  
Più in particolare, le saranno proposti nell’arco di 14 mesi: 
 
sette appuntamenti di valutazione della salute fisica che potrebbero comprendere: 
 
 questionari su abitudini alimentari, attività fisica, qualità della vita in relazione alla salute e 
soddisfazione nei riguardi del Servizio che potrà compilare con l’aiuto di uno psicologo o del medico del 
nostro Servizio che la segue; 
 valutazione della salute fisica nel corso di una visita ambulatoriale periodica del medico, con raccolta 
di informazioni relative al passato e attuale stato di salute fisica; 
 un esame del sangue che comprende alcune indagini di routine come la glicemia, colesterolo (LDL e 
HDL), trigliceridi, vitamina D; 
 un Elettrocardiogramma per vedere come funziona il suo cuore; 
 una densitometria ossea total body per vedere lo stato delle sue ossa. 
 
Lei potrà essere assegnato casualmente al gruppo che comprende la valutazione della salute fisica in 
aggiunta al trattamento abituale, oppure al gruppo che prevede la valutazione della salute fisica in aggiunta  
ad incontri di informazione sulla corretta alimentazione e attività fisica. Noi non sappiamo se tale modalità sia 
o meno efficace nel promuovere la salute fisica, ed è per questo che effettuiamo questo studio. 
In ogni caso le verrà garantita la prosecuzione del suo trattamento già in corso. 
I suoi familiari potranno essere invitati a partecipare ad un incontro informativo. 
 
 
Tutte le informazioni connesse alla Sua partecipazione saranno trattate in modo strettamente riservato in 
conformità alle norme sul trattamento dei dati personali (legge 30 giugno 2003, n.196 e successive 
modifiche ed integrazioni). 
 
La Sua collaborazione è molto importante! Le informazioni che Lei ci darà ci permetteranno infatti di 
comprendere meglio i bisogni degli utenti del Servizio e di migliorarne l’organizzazione.  
La partecipazione a questo progetto è completamente volontaria. Lei è libera/o di non partecipare o di 
ritirarsi in qualsiasi momento, senza per questo dover dare alcuna spiegazione; in ogni caso il nostro 
Servizio continuerà a garantirle, con la dovuta attenzione, tutta l’assistenza sanitaria di cui ha bisogno.  
 
 
Per chiarimenti potrà rivolgersi in qualsiasi momento direttamente a: 
 
Prof.   Lorenzo Burti 
Tel. 045 8127442 
 
Verona,__________   Firma del paziente ‘per presa visione’ _____________________________ 
 
 
Verona,__________                        Firma dell’intervistatore  _____________________________ 
  iii 
Informativa e manifestazione del consenso al trattamento dei dati personali 
(ex art. 13 del D.Lgs. 196/2003) per il paziente 
 
Titolari del trattamento e relative finalità 
 
Il Centro di sperimentazione (3° Servizio Psichiatrico Territoriale del Dipartimento Interaziendale per la 
Salute Mentale) e l'Azienda (ULSS 20, finanziamento fondazione CariVerona), che ha commissionato lo 
studio che Le è stato descritto, ciascuno per gli ambiti di propria competenza e in accordo alle responsabilità 
previste dalle norme della buona pratica clinica (D.Lgs. 211/2003), tratteranno i Suoi dati personali, in 
particolare quelli sulla salute e, soltanto nella misura in cui sono indispensabili in relazione all'obiettivo dello 
studio, altri dati relativi ai Suoi dati socio-anagrafici e ai Suoi stili di vita, esclusivamente in funzione della 
realizzazione dello studio. 
A tal fine i Suoi dati personali sopra elencati saranno raccolti dal Centro di sperimentazione. 
Il trattamento dei dati personali relativi a informazioni socio-anagrafiche, utilizzo dei Servizi Sanitari, stato di 
salute (inclusi parametri vitali, peso e statura) e trattamenti in atto, stili di vita, qualità di vita e opinione sui 
Servizi Psichiatrici è indispensabile allo svolgimento dello studio e, pertanto, il rifiuto di conferirli non Le 
consentirà di parteciparvi. 
 
Natura dei dati 
 
Il medico che La seguirà nello studio, La identificherà con un codice. I dati che La riguardano, raccolti nel 
corso dello studio, ad eccezione del Suo nominativo, saranno trasmessi al Centro di sperimentazione, 
registrati, elaborati e conservati unitamente a tale codice, ai dati socio-anagrafici, al Suo peso e alla Sua 
statura e a tutte le variabili relative allo stato di salute e agli stili vita. Soltanto il medico sperimentatore e i 
soggetti autorizzati potranno collegare questo codice al Suo nominativo. 
 
Modalità del trattamento 
 
I dati, trattati mediante strumenti anche elettronici, saranno diffusi solo in forma rigorosamente anonima, ad 
esempio attraverso pubblicazioni scientifiche, statistiche e convegni scientifici. La Sua partecipazione allo 
studio implica che il personale del Centro di sperimentazione, il Comitato etico della Azienda Ospedaliera 
Universitaria Integrata di Verona, il Comitato Etico dell’Azienda Ospedaliera Universitaria Integrata e le 
autorità sanitarie italiane e straniere potranno conoscere i dati che La riguardano, contenuti anche nella Sua 
documentazione clinica originale, con modalità tali da garantire la riservatezza della Sua identità. 
 
Esercizio dei diritti 
 
La informiamo, inoltre, che Lei potrà, in ogni momento, esercitare i diritti di cui all'art. 7 del D.Lgs. 196/2003 – 
quali ad esempio: accedere ai Suoi dati personali, integrarli, aggiornarli, rettificarli, opporsi al loro trattamento 
per motivi legittimi, ecc. - rivolgendosi direttamente al Centro di sperimentazione (Lorenzo Burti, tel. 
045/8127442, e-mail lorenzo.burti@univr.it). 
In ogni momento, inoltre, potrà interrompere, senza fornire alcuna giustificazione, la Sua partecipazione allo 
studio. In tal caso, i campioni biologici a Lei correlati verranno distrutti e non saranno raccolti ulteriori dati 
personali che La riguardano, ferma restando l'utilizzazione di quelli eventualmente già raccolti per 





Io sottoscritta/o ZZZZZZZZZZZZZ(riportare nome e cognome in stampatello) acconsento al 
trattamento dei miei dati personali per gli scopi della ricerca, nei limiti e con le modalità indicate 




Data __________________ Firma leggibile dell'interessato ________________________ 
 
  iv 
INFORMAZIONI PER IL MEDICO DI FAMIGLIA 
 
Verona, 
Egr. Collega,  
 
La informiamo che il Suo assistito Sig./Sig.ra____________________________________ 
ha acconsentito di partecipare alla seconda fase dello studio epidemiologico dal titolo:  
 
PHYSICO - DSM – VR 
 PHYSICAL CO-MORBIDITY, POOR HEALTH BEHAVIOUR AND HEALTH PROMOTION IN VERONA 
PATIENTS WITH FUNCTIONAL PSYCHOSES: A PREVALENCE STUDY AND A RANDOMISED 
CONTROLLED STUDY 
(PHYSICO- Comorbilità fisica, comportamenti a rischio e promozione della salute in pazienti con psicosi 
funzionale a Verona: studio di prevalenza e studio controllato randomizzato) 
 
in corso presso i quattro Servizi Psichiatrici Territoriali dell’ULSS 20 di Verona. Lo studio ha ricevuto 
l’approvazione del Comitato Etico della Provincia di Verona e del Comitato Etico dell’Azienda Ospedaliera 
Universitaria Integrata. 
 
Questo progetto intende studiare la prevalenza della comorbilità fisica e dei comportamenti a rischio per la 
salute nei pazienti affetti da psicosi funzionale in carico al Servizio Psichiatrico Territoriale di Verona (prima 
fase). La successiva seconda fase ha l’obiettivo di implementare strategie di promozione della salute 
attraverso il monitoraggio della salute e interventi sull’alimentazione e l’attività fisica.  
 
In particolare la seconda fase dello studio prevede l’inserimento dei soggetti ai quali saranno proposti 
nell’arco di 14 mesi: 
- sette appuntamenti di valutazione della salute fisica che possono comprendere: 
 questionari su abitudini alimentari, attività fisica, qualità della vita in relazione alla salute e 
soddisfazione nei riguardi del Servizio che il soggetto potrà compilare con l’aiuto di uno psicologo o del 
medico del nostro Servizio che lo segue; 
 valutazione della salute fisica nel corso di una visita ambulatoriale periodica del medico, con raccolta 
di informazioni relative al passato e attuale stato di salute fisica; 
 un esame del sangue che comprende alcune indagini di routine come la glicemia, colesterolo (LDL e 
HDL), trigliceridi, vitamina D; 
 un Elettrocardiogramma; 
 una densitometria ossea total body. 
 
La valutazione della salute fisica, sarà accompagnata, o meno, secondo una scelta casuale, a incontri di 
informazione sulla corretta alimentazione e attività fisica. Noi non sappiamo se tale modalità sia o meno 
efficace nel promuovere la salute fisica, ed è per questo che effettuiamo questo studio. 
 
I soggetti potranno essere assegnati, secondo una scelta casuale, ad uno o all’altro programma. In ogni 
caso, i pazienti avranno l’opportunità di parlare con i terapeuti della loro salute fisica, oltre che mentale e 
verrà garantita la prosecuzione del trattamento già in corso. 
 
Ovviamente il Sig./la Sig.ra________________________________________ 
ha acconsentito affinché Lei venisse informato della sua partecipazione allo studio. 
 
Qualora lo riterrà opportuno, ci rendiamo disponibili ad incontrarLa per fornire tutte le precisazioni e i 
ragguagli in merito.  
 




   _______________________ 
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Questionario "Progressi delle Aziende Sanitarie per la Salute 
in Italia (PASSI)"
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Ora di inizio dell'intervista _______  
 
- Le chiederò ora alcune informazioni generali sul suo stato di salute…  
1.1 Come va in generale la sua salute?  
Leggere le possibili risposte  




Molto male  
Non leggere  
    Non so  
 
 
Ora vorrei farle alcune domande sul suo stato di salute durante gli ultimi trenta giorni  
1.2 Consideri le sue condizioni fisiche, comprese malattie e conseguenze di incidenti. Per  
quanti giorni, negli ultimi 30 giorni, non si è sentito bene?  
 
Numero di giorni _ _  
Non so/non ricordo  
 
 
1.3 Adesso pensiamo agli aspetti psicologici, quali problemi emotivi, ansia, depressione,  
stress. Per quanti giorni, negli ultimi 30 giorni, non si è sentito bene?  
 
Numero di giorni _ _  
Non so/non ricordo  
 
 
1.4 Ora consideriamo le sue abituali attività. Per quanti giorni, negli ultimi 30 giorni, non è stato  
in grado di svolgerle a causa del cattivo stato di salute fisica o psicologica?  
Numero di giorni _ _  
Non so/non ricordo  
 
 
1.5 Negli ultimi 12 mesi, si è sottoposto ad almeno una visita del suo medico di famiglia  
per un motivo di salute?  





ricetta, ma  
per check-up  
generali e  
problemi 
specifici  
di salute  
Si  
No  
Non so/non ricordo  
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- infarto del miocardio  
 
 
- altre malattie del cuore  
 
 
- ictus  
 
 
- malattie respiratorie  
 
 
- diabete  
 
 
- tumore maligno  
□ Si □ No  
 
 
□ Si □ No  
 
 
□ Si □ No  
 
 
□ Si □ No  
 
 
□ Si □ No  
 
 




1.7 Ha fatto la vaccinazione antinfluenzale negli ultimi 12 mesi?  
Si  
No  








Ora vorrei farle alcune domande sull' attività fisica svolta sia durante sia fuori dal lavoro  
2.1 Lei lavora?  
Regolarment
e:  




Si, regolarmente  
Si, ma non regolarmente (saltare alla domanda 2.3)  
No (saltare alla domanda 2.3)  





2.2 Durante il suo lavoro prevalentemente:  
Leggere (una sola risposta possibile)  
sta seduto o in piedi  
cammina  
svolge un lavoro pesante dal punto di vista fisico  
Non leggere  
   altro  
 
 
Qualche domanda sull'attività fisica svolta fuori dal lavoro  
 
 
2.3 In una settimana tipo della sua vita, svolge qualche attività moderata per almeno 10  
minuti che comporti un leggero aumento della respirazione e del battito cardiaco o un  
po' di sudorazione?  













No (saltare alla domanda 2.6)  





















2.4 Per quanti giorni alla settimana?  
__ __ gg/settimana  
Non so/non ricordo  
 
 
2.5 Per quanti minuti al giorno in media?  
__ __ __ minuti al giorno  
Non so/non ricordo  
 
 
2.6 In una settimana tipo della sua vita, svolge qualche attività intensa per almeno 10  
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velocemente,  
fare sport  
agonistici  
Si  
No (saltare alla domanda 2.9)  
Non so/non sono sicuro (saltare alla domanda 2.9)  
 
 
2.7 Per quanti giorni alla settimana?  
__ __ gg/settimana  
Non so/non ricordo  
 
 
2.8 Per quanti minuti al giorno in media?  
__ __ __ minuti al giorno  
Non so/non ricordo  
 
 
Adesso le faccio qualche domanda su eventuali consigli che ha ricevuto sull'attività 
fisica  
2.9 Le è mai stato chiesto da un medico o altro operatore sanitario se svolge  
regolarmente attività fisica?  
Si  
No  





2.10 Le è stato mai consigliato da un medico o altro operatore sanitario di svolgere  
regolare attività fisica?  
Si  
No (saltare alla sezione 3: Abitudine al fumo)  
Non so/non ricordo (saltare alla sezione 3: Abitudine al fumo)  
 
 
2.11 A quale scopo le è stato consigliato di svolgere attività fisica?  
Per un problema attuale di salute  
A scopo preventivo Entrambe le 
ragioni Non so/non ricordo  
 
 
2.12 Le è stato raccomandato o suggerito qualche tipo di attività fisica in particolare?  
Si  
No (saltare alla sezione 3: Abitudine al fumo)  
Non so/non ricordo (saltare alla sezione 3: Abitudine al fumo)  
 
 
2.13 Le ha parlato della frequenza e della durata dell'attività fisica che dovrebbe fare?  
Si  
No  
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2.14 Le ha chiesto, alle visite successive, se sta svolgendo le attività suggerite?  
Si  
No  
Non l'ho visto da quando ho ricevuto i consigli  











Passiamo ora ad alcune domande sul suo comportamento e la sua abitudine al fumo  




Non sono stato dal medico negli ultimi 12 mesi  
Non so/non ricordo  
 
 
3.2 Ha mai fumato almeno 100 sigarette (5 pacchetti da 20 sigarette) nella sua vita?  
Si  
No (saltare alla domanda 3.15)  
 
 
3.3 Attualmente fuma?  
Si  
No (saltare alla domanda 3.11)  
 
 
3.4 A che età ha iniziato a fumare?  
__ __ anni  
Non so/non ricordo  
 
 
3.5 In media quante sigarette fuma al giorno?  
N. |_|_|  
Meno di una sigaretta al giorno  
Non so/non ricordo  
 
 
3.6 La recente Legge che vieta di fumare nei bar, ristoranti e altri spazi pubblici ha  
influenzato il numero di sigarette che fuma?  
Se la 








numero di  
sigarette  
Si, ha diminuito il numero di sigarette  
Si, ha aumentato il numero di sigarette (saltare alla domanda 3.8)  
No (saltare alla domanda 3.8)  
Non sa rispondere (saltare alla domanda 3.8)  
  xxx 
 






3.8 Un medico o altro operatore sanitario le ha mai consigliato di smettere di fumare?  
Si, per motivi di salute  
Se la 





Si, a scopo preventivo  
Si, per entrambe le ragioni  
No  
Non so/non ricordo  
 
3.9 Durante gli ultimi 12 mesi, ha smesso di fumare per almeno un giorno nel tentativo di  
smettere definitivamente?  
 






Si, una volta  
Si, più di una volta  
No  
Non so/non ricordo  
 
 
3.10 Ha mai partecipato ad un corso/programma che l'aiutasse a smettere di fumare?  
Si, organizzato dalla ASL  
 






Si, organizzato da un'associazione  
Si, organizzato da un medico privato  
Si, organizzato da altri  
Si, non ricorda da chi è stato organizzato  
No  
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SOLO PER GLI EX-FUMATORI  
(hanno fumato almeno 100 sigarette nelle loro vita e NON fumano attualmente)  
 
 
3.11 Quando ha smesso di fumare?  
Meno di 6 mesi fa  
Tra 6 mesi a 1 anno fa  
Tra 1 e 2 anni fa  
Più di 2 anni fa  




3.12 Come è riuscito a smettere di fumare? (si possono barrare più caselle)  
Da solo, senza aiuto (saltare alla domanda 3.14)  
Con l'aiuto di un medico o altro operatore sanitario  
Partecipando a gruppi di aiuto  
Con l'assunzione di farmaci tradizionali (inclusi cerotti e simili)  
Ricorrendo a terapie non convenzionali (agopuntura, fitofarmaci)  
Con altro metodo  
 
 
3.13 Ha partecipato ad un corso/programma che l'ha aiutata a smettere di fumare?  
Si, organizzato dalla ASL  
 






Si, organizzato da un'associazione  
Si, organizzato da un medico privato  
Si, organizzato da altri  
Si, non ricorda da chi è stato organizzato  
No  
Non so/non ricordo  
 
 
3.14 Lei sa che in Italia esistono leggi che proibiscono di fumare nei luoghi pubblici. Che  
ruolo hanno avuto nella sua decisione di smettere di fumare?  
Leggere  
Un ruolo decisivo  
È stato uno dei fattori che ho considerato, ma non il più importante  
Nessun ruolo  
Ho smesso di fumare prima di queste leggi  
Non leggere  






  xxxii 
PER TUTTI (NON FUMATORI, FUMATORI, ED EX-FUMATORI)  
Vorrei ora chiederle qualcosa sull'esposizione al fumo in casa e nel luogo di lavoro  
 
3.15 Quale affermazione meglio descrive le regole sul fumo all'interno di casa sua?  
Leggere  










Non leggere  
È permesso fumare in alcuni luoghi o in alcuni orari o situazioni  
È permesso fumare ovunque  
Non ci poniamo il problema perché nessun frequentatore della  
casa fuma  
 
 
Non so/non sono sicuro  
 
 
Se la persona lavora regolarmente (domanda 2.1), continuare. Altrimenti, saltare alla SEZIONE 4  
 
 
3.16 Quando lavora, si trova in un ambiente chiuso per la maggior parte del tempo?  
Si  
No (saltare alla Sezione 4)  
 
3.17 Direbbe che le persone con cui lavora e i suoi clienti o visitatori:  
Leggere  
Rispettano sempre i divieti di fumo  
Li rispettano a volte Non li 
rispettano mai  
Il mio luogo di lavoro è esente dalle leggi correnti  
Non so  
 
 
SEZIONE 4: Alimentazione  
____________________________________________________________________________  
Passiamo ora ad alcune domande relative alle abitudini alimentari. Vorrei chiederle di  
alcuni cibi che normalmente mangia o beve. Mi dica, per cortesia, quanto volte in media  
mangia o beve ciascuno dei cibi che le chiederò (ad esempio una volta al giorno, due volte  
a settimana, tre volte al mese, ecc.)  
 
 
4.1 Quante volte beve succhi di frutta confezionati (escluse spremute)?  
___ volte giorno  
___ volte settimana  
___ volte mese  
___ volte anno  
raramente/mai  
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4.2 Quante volte beve spremute e/o frullati di frutta?  
___ volte giorno  
___ volte settimana  
___ volte mese  
___ volte anno  
raramente/mai  
non so/non ricordo  
 
 
4.3 Quante volte mangia la frutta?  
___ volte giorno  
___ volte settimana  
___ volte mese  
___ volte anno  
raramente/mai  
non so/non ricordo  
 
 
4.4 Quante volte mangia verdure ed ortaggi (insalata, pomodori, zucchine ecc…)  
___ volte giorno  
___ volte settimana  
___ volte mese  
___ volte anno  
raramente/mai  
non so/non ricordo  
 
 
4.5 Ha mai sentito parlare dell'importanza di consumare almeno 5 porzioni tra frutta e  
verdura al giorno?  
Si  
No (saltare alla domanda 4.7)  
Non so/non ricordo (saltare alla domanda 4.7)  
 
4.6 Da chi ne ha sentito parlare?  
Leggere (è possibile barrare più di una risposta)  
Medico o altro operatore sanitario  
Televisione, radio o giornali  
Amici /famigliari  
Campagne informative, associazioni di categoria, Coop, Conad…  













4.7 Quante volte mangia il pesce fresco o surgelato?  
considera
re  





___ volte giorno  
___ volte settimana  
___ volte mese  
___ volte anno  
raramente/mai  
non so/non ricordo  
 
 
4.8 Quante volte mangia i legumi (fagioli, lenticchie, ceci, piselli, ecc.)?  
___ volte giorno  
___ volte settimana  
___ volte mese  
___ volte anno  
raramente/mai  
non so/non ricordo  
 
 
Adesso le farò alcune domande sul suo peso e sulla sua abitudine al controllo del peso  
 
 
4.9 Negli ultimi 12 mesi, un medico o altro operatore sanitario le ha dato dei consigli sul  
suo peso corporeo?  
Se la 
risposta  
è SI  
chiedere il  
tipo di  
consiglio  
Si, perdere peso  
Si, aumentare di peso Si, 
mantenere il peso  
Non sono stato dal medico negli ultimi 12 mesi  
No  
Non so/non ricordo  
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SEZIONE 5: Assunzione di alcol  
____________________________________________________________________________  
Ora le farò alcune domande sulle bevande alcoliche. Una unità di bevanda alcolica equivale 
ad una lattina di birra o ad un bicchiere di vino o ad un bicchierino di liquore.  
 
 
5.1 Durante gli ultimi 30 giorni, quanti giorni ha bevuto almeno una unità di bevanda  
alcolica?  
____ giorni alla settimana  
____ giorni al mese  
nessuna bevanda alcolica nell'ultimo mese (saltare alla domanda 5.6)  
non so/non ricordo (saltare alla domanda 5.6)  
 
 
5.2 Nell'ultima settimana, quante unità di bevande alcoliche ha bevuto in media ogni  
giorno?  
N° __ __  
non so/non ricordo  
 
 
5.3 Considerando tutti i tipi di bevande alcoliche, quante volte nell'ultimo mese ha bevuto  
6 o più unità in una unica occasione?  
N° __ __  
non so/non ricordo  
 
 
5.4 Quante volte nell'ultimo mese ha bevuto almeno una unità di bevanda alcolica fuori  
dai pasti?  
____ giorni alla settimana  
____ giorni al mese  
nessuna bevanda alcolica fuori pasto nell'ultimo mese  
non so/non ricordo  
 
 
5.5 Durante gli ultimi 30 giorni, quante volte ha guidato entro un'ora dall'aver bevuto 2 o  
più unità di una bevanda alcolica?  
 
 
Non ho guidato nell'ultimo mese  
Mai  
1-2 volte 3-4 
volte  
Più di 4 volte  
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5.6 Durante gli ultimi 30 giorni, quante volte è salito in auto o in moto con un guidatore  
che aveva bevuto, nell'ora precedente, 2 o più unità di una bevanda alcolica?  
Mai  
1-2 volte 3-4 volte  
Più di 4 volte  
Non so/non ricordo  
 
 
5.7 Durante gli ultimi 12 mesi, un medico o altro operatore sanitario le ha mai chiesto  
quanto alcol beve?  
Si  
No  
Non ho visto il medico negli ultimi 12 mesi  
Non so/non ricordo  
 
 








ha avuto il  
consiglio  
Si, il medico o un operatore sanitario  
Si, famigliari o amici  
Si, altro  
No, non mi è stato consigliato  






SEZIONE 6: Rischio cardiovascolare  
____________________________________________________________________________  
Vorrei farle qualche domanda sugli esami medici e sui farmaci che le sono stati prescritti o  
consigliati dal suo medico  
 
6.1 Un medico o altro operatore sanitario le ha mai misurato la pressione arteriosa?  
Si  
No (saltare alla domanda 6.5)  
Non so/non ricordo (saltare alla domanda 6.5)  
 
 
6.2. Quando è stata l'ultima volta?  
Nell'ultimo anno (ultimi 12 mesi)  
1-2 anni fa (da 1 a meno di 2 anni fa)  
Più di 2 anni fa  





  xxxvii 
6.3 Un medico o altro operatore sanitario le ha mai detto che ha la pressione alta?  
Si  
No (saltare alla domanda 6.5)  
Non so/non ricordo (saltare alla domanda 6.5)  
 
 
6.4 Che tipo di trattamento sta seguendo attualmente per tenere sotto controllo la sua  
pressione?  
Leggere e rispondere ad ogni punto  
 
 
a. Farmaci  
b. Attenzione al sale nel cibo  
c. Attività fisica regolare  















6.5 Il colesterolo è un grasso nel sangue. Le è mai stato misurato?  
Si  
No (saltare alla domanda 6.11)  




6.6 Quando è stata l'ultima volta?  
Nell'ultimo anno (ultimi 12 mesi)  
Più di un anno fa  
Non so/non ricordo  
 
 
6.7 Un medico o altro operatore sanitario le ha mai detto che ha il colesterolo alto?  
Si  
No (saltare alla domanda 6.11)  
Non so/non ricordo (saltare alla domanda 6.11)  
 
6.8 Prende attualmente farmaci per tenere basso il colesterolo?  
Si (saltare alla domanda 6.10)  
No  
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6.9 Perché non prende farmaci?  
Leggere tutte le risposte e barrarne solo una  
Perché il colesterolo si è abbassato senza farmaci  
A causa degli effetti collaterali  
Non mi sono stati prescritti  
Altro  
Non so/non ricordo  
 
 
6.10 Escludendo i farmaci, cosa sta facendo per mantenere basso il suo livello di  
colesterolo?  
Leggere e rispondere ad ogni punto  
 
 
a. Minor consumo di carne e formaggi  
b. Attività fisica regolare  
c. Perdita o controllo peso corporeo  
d. Aumento di frutta e verdura nell'alimentazione  
 
 
6.11 Un medico le ha mai misurato la glicemia?  
Si  













  Non so/non ricordo (saltare alla domanda 6.13)  
 
6.12 Quando è stata l'ultima volta?  
Nell'ultimo anno (ultimi 12 mesi)  
1-2 anni fa (da 1 a meno di 2 anni fa)  
Più di 2 anni fa  
Non so/non ricordo  
 
I medici di medicina generale e altri operatori di salute hanno cominciato a calcolare il  
punteggio di rischio cardiovascolare, che serve per valutare il rischio di infarto usando i 
valori di glicemia, colesterolo e pressione.  
 
 
6.13 Un medico o altro operatore sanitario le ha calcolato questo punteggio?  
Si  
No  
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SEZIONE 7: Sicurezza stradale  
____________________________________________________________________________  
Ora le chiederò alcune informazioni sull'uso dei dispositivi di sicurezza stradale  
 
 
7.1 Quanto spesso mette la cintura in auto quando è seduto sui sedili anteriori?  
Sempre  
Quasi sempre 
Qualche volta  
Raramente  
Mai  
Non viaggio mai sui sedili anteriori  
Non vado in auto (saltare alla domanda 7.3)  
 
 
7.2 Quanto spesso mette la cintura in auto quando è seduto sui sedili posteriori?  
Sempre  
Quasi sempre 
Qualche volta  
Raramente  
Mai  
Non viaggio mai sui sedili posteriori  
 
 
7.3 Negli ultimi 12 mesi, è mai salito su una motocicletta/scooter/motorino, come  
guidatore o passeggero?  
Si  
No (saltare alla Sezione 8)  
Non so/non ricordo (saltare alla Sezione 8)  
 
 
7.4 Quanto spesso ha messo il casco?  
Sempre  
Quasi sempre 
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SEZIONE 8: Screening oncologici  
____________________________________________________________________________  
Le spiace se le richiedo per verifica la sua età?  
 
(Riscrivere l'età:____ anni)  
Saltare alla SEZIONE 9 se l'intervistato è DONNA che ha MENO di 25 anni 
Saltare alla SEZIONE 10 se l'intervistato è UOMO che ha MENO di 50 anni  
Saltare alla DOMANDA 8.15 se l'intervistato è UOMO che ha PIU' di 50 anni  
 
 
Proseguo con qualche domanda sul Pap-Test. Il Pap-Test serve a ricercare eventuali lesioni  
al collo dell'utero.  
 
 
8.1 Ha mai ricevuto una lettera dalla sua ASL che la invitava a fare un Pap-Test?  
Si  
No  
Non so/non ricordo  
 
 
8.2 Le è mai stato consigliato dal suo medico o da un ginecologo di fare regolarmente  
l'esame del Pap-Test a scopo preventivo?  
Si  
No, perché ho già avuto un intervento di isterectomia  
No  
Non so/non ricordo  
 
 
8.3 Nel corso della sua vita ha eseguito un Pap-Test a scopo preventivo in assenza di  
sintomi o disturbi?  
Si  
No (per le donne di 50 anni o più, saltare alla domanda 8.8; altrimenti, saltare alla  
Sezione 9)  
Non so (per le donne di 50 anni o più, saltare alla domanda 8.8; altrimenti, saltare alla  
Sezione 9)  
 
 
8.4 A che età ha eseguito il suo primo Pap-Test?  
__ anni  
non so/non ricordo  
 
 
8.5 Quando è stata l'ultima volta che ha fatto l'ultimo Pap-Test?  
Durante l'ultimo anno (ultimi 12 mesi)  
Da 1 a 2 anni fa (da 1 a meno di 2 anni fa)  
Da 2 a 3 anni (da 2 a meno di 3 anni fa)  
Più di 3 anni fa  
Non ricordo  
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8.6 Dove ha eseguito il suo ultimo Pap-Test?  
Leggere  
Presso una struttura pubblica  
Presso un struttura privata  
Non leggere  
Non so/non ricordo  
 
 
8.7 Quale è stata la principale motivazione che l'ha spinta ad effettuare l'ultimo Pap-Test?  
Leggere (barrare solo una casella)  
Una lettera dell'Asl che mi invitava ad eseguire il Pap-Test  
Il consiglio del medico di famiglia  
Il consiglio di un medico specialista  
Di propria iniziativa  
Altro  
Non leggere  
Non so/non ricordo  
Non vuole rispondere  
 
 
Se la donna ha MENO di 50 anni, saltare alla SEZIONE 9  
 
 
Vorrei farle una serie di domande sulla mammografia. La mammografia è una  
radiografia del seno fatta per ricercare eventuali lesioni alla mammella.  
 
 
8.8 Ha mai ricevuto una lettera dalla sua ASL che la invitava a fare una mammografia?  
Si  
No  




8.9 Le è mai stato consigliato dal suo medico o ginecologo di sottoporsi a regolari  
mammografie a scopo preventivo?  
Si  
No  
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8.10 Ha mai fatto una mammografia, in assenza di sintomi o disturbi?  
Si  
No (saltare alla domanda 8.15)  




8.11 A che età ha eseguito la sua prima mammografia?  
__ anni  
non so/non ricordo  
 
 
8.12 Quando è stata l'ultima volta che ha fatto una mammografia?  
Durante l'ultimo anno (ultimi 12 mesi)  
Da 1 a 2 anni fa (da 1 a meno di 2 anni fa)  
Da 2 a 3 anni (da 2 a meno di 3 anni fa)  
Più di 3 anni fa  
Non ricordo  
 
 
8.13 Quale è stata la principale motivazione che l'ha spinta ad effettuare l'ultima  
mammografia?  
Leggere (barrare solo una casella)  
Una lettera dell'Asl che mi invitava ad eseguire la mammografia  
Il consiglio del medico di famiglia  
Il consiglio di un medico specialista  
Di propria iniziativa  
Altro  
Non leggere  
Non so/non ricordo  
Non vuole rispondere  
 
 
8.14 Dove ha eseguito l'ultima mammografia?  
Leggere  
Presso una struttura pubblica  
Presso un struttura privata  
Non leggere  
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PER UOMINI E DONNE SOPRA I 50 ANNI  
 
 
Vorrei farle qualche domanda sullo screening per il cancro colon-rettale. Esiste un test per  
verificare la presenza nelle feci di sangue non visibile, chiamato "ricerca del sangue  




8.15 Ha mai eseguito un test per la presenza di sangue occulto nelle feci?  
Si  
No (saltare alla domanda 8.18)  
Non so (saltare alla domanda 8.18)  
 
 
8.16 Questo esame faceva parte di un controllo preventivo o l'ha fatto per problemi di  
salute?  
Controllo preventivo  
Problemi di salute  
Non so/non ricordo  
 
8.17 Quando è stata l'ultima volta che ha fatto un test per la ricerca del sangue occulto?  
Durante l'ultimo anno (ultimi 12 mesi)  
Da 1 a 2 anni fa (da 1 a meno di 2 anni fa)  
Più di 2 anni fa  




8.18 Ci sono altri test che si eseguono a volte nello screening di questo tipo di tumore, nei  
quali si inserisce una sonda nell'intestino per vedere se ci sono eventuali lesioni. 
Questi test si chiamano rettoscopia e colonscopia. Ha mai eseguito questi test?  
Si  
No (saltare alla Sezione 10)  
non so (saltare alla Sezione 10)  
 
 
8.19 Questi test facevano parte di un controllo preventivo o li ha fatti per problemi di  
salute?  
Controllo preventivo  
Problemi di salute  










  xliv 
8.20 Quando è stata l'ultima volta che ha fatto una rettoscopia o colonscopia?  
Durante l'ultimo anno (ultimi 12 mesi)  
Da 1 a 2 anni fa (da 1 a meno di 2 anni fa)  
Più di 2 anni fa  
Non ricordo  








Per le DONNE che hanno MENO di 50 anni  
 
 
La rosolia è una malattia infettiva pericolosa in gravidanza.  
9.1 Per questa malattia esiste una vaccinazione. E' mai stata vaccinata contro la rosolia?  
 
Si (Saltare alla sezione 10)  
No  
Non so/non ricordo  
 
 




9.2 Ha mai eseguito questo esame?  
Si  
No  
Non so/non ricordo  
 
 
9.3 Quale è stato l'esito dell'esame?  
Risulta che ho avuto la rosolia  
Risulta che non ho avuto la rosolia  
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Abbiamo quasi finito. Le faccio le ultimissime domande  
 
 







10.2 Qual è il titolo di studio da lei conseguito?  
Non leggere  
Nessun titolo  
Licenza elementare  
Licenza di scuola media inferiore  
Diploma o qualifica di scuola media superiore  
Laurea o Diploma universitario  
In altra condizione  
 
 
10.3 Qual è la sua cittadinanza?  
Italiana  
Straniera (Specificare____________________ )  
 
 
Le ultime due domande  
 
 
10.4  Può dirmi la sua altezza (senza scarpe)?  
__________ cm  
 
 
10.5 Può dirmi il suo peso senza scarpe e abiti o con abiti leggeri?  
__________ Kg  
 
 





Fine intervista (ora/min.) _____________  
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